



## Impact of Male Pattern Baldness on Coronary Heart Disease: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002537
Article Type:	Research
Date Submitted by the Author:	28-Dec-2012
Complete List of Authors:	Yamada, Tomohide; University of Tokyo, Department of Diabetes and Metabolic Diseases Hara, Kazuo; University of Tokyo, Department of Diabetes and Metabolic Diseases Kadowaki, Takashi; University of Tokyo, Department of Diabetes and Metabolic Diseases
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Cardiovascular medicine, Diabetes and endocrinology, Diagnostics, Epidemiology, Health economics
Keywords:	Coronary heart disease < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, Adult dermatology < DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6 **Impact of Male Pattern Baldness on Coronary Heart Disease: A meta-analysis**  
7

8 Tomohide Yamada, MD

9  
10  
11 Kazuo Hara, MD, PhD\*

12  
13  
14 Takashi Kadowaki, MD, PhD

15  
16  
17 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine

18  
19  
20 University of Tokyo, Japan

21  
22  
23 \* Corresponding author

24  
25  
26 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan

27  
28  
29 Tel.: +81-3-5800-8818; Fax: +81-3-5689-7209

30  
31  
32 E-mail address: haratky@gmail.com

33  
34  
35  
36  
37  
38 **Brief title:** Male pattern baldness and CHD

39  
40  
41  
42  
43  
44 **Word count:** 3,224 words (Abstract: 276+Body of the text: 2,948)

1  
2  
3  
4  
5  
6 **Abstract**  
7

8  
9 **Objective:**

10  
11 To confirm the association of male pattern baldness with coronary heart disease (CHD).  
12  
13

14  
15 **Design:**

16  
17 Meta-analysis of observational studies.  
18  
19

20  
21 **Data sources:**

22  
23 Medline and the Cochrane Library were searched for articles published up to November 2012 using  
24  
25 keywords that included both baldness and coronary heart disease, and references of the identified  
26  
27 studies were also searched.  
28  
29  
30

31  
32 **Study selection:**

33  
34 Observational studies were identified that reported risk estimates for CHD related to baldness. Two  
35  
36 observers independently assessed eligibility, extracted data, and assessed the possibility of bias.  
37  
38  
39

40  
41 **Data synthesis:**

42  
43 The adjusted relative risk (RR) and 95% confidence interval (95%CI) were calculated with the  
44  
45 DerSimonian-Laird random-effect model.  
46  
47  
48

49  
50 **Results:**

51  
52 From 850 possible studies, 3 cohort studies and 3 case-control studies were selected (36,990  
53  
54 subjects).  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 In the cohort studies, the adjusted RR of men with severe baldness for CHD was 1.32 (95%CI:  
7  
8  
9 1.08-1.63, P=0.008, I squared=25%) versus those without baldness. Analysis of younger men (<55  
10  
11  
12 or ≤60 years) showed a similar association of CHD with severe baldness (RR: 1.44, 95%CI:  
13  
14  
15 1.11-1.86, P=0.006, I squared=0%).

16  
17  
18 In 3 studies employing the modified Hamilton scale, vertex baldness was associated with CHD and  
19  
20  
21 the relation depended on the severity of baldness (severe vertex: RR 1.48 (1.04-2.11, P=0.03);  
22  
23  
24 moderate vertex: RR 1.36 (1.16-1.58, P<0.001); mild vertex: RR 1.18 (1.04-1.35, P<0.001).  
25  
26  
27 However, frontal baldness was not associated with CHD (RR 1.11 (0.92-1.32, P=0.28)).

#### 28 29 **Conclusion:**

30  
31  
32 Vertex baldness, but not frontal baldness, is associated with an increased risk of CHD. The  
33  
34  
35 association with CHD depends on the severity of vertex baldness and also exists among younger  
36  
37  
38 men. Thus, vertex baldness may be more closely related to atherosclerosis than frontal baldness, but  
39  
40  
41 the relation between male pattern baldness and CHD deserves further investigation.

42  
43  
44  
45  
46 **Key words:** male pattern baldness, androgenetic alopecia, coronary heart disease, relative risk,  
47  
48  
49 meta-analysis  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article summary

### Article focus:

• The present meta-analysis aimed to confirm the association of male pattern baldness (androgenetic alopecia) with an increased risk of coronary heart disease (CHD).

### Key messages:

• Meta-analysis of 6 observational studies with 36,690 subjects showed that vertex baldness is associated with an increased risk of CHD and that the relationship depends on the severity of baldness, while frontal baldness is not.

• Thus, vertex baldness may be a marker of CHD and is more closely associated with systemic atherosclerosis than frontal baldness.

• This potential relationship should be investigated by further studies, including well-designed prospective studies.

### Strengths and limitations of this study:

• This was the first meta-analysis of the relation between baldness and CHD; it showed that the relationship depends on the severity of baldness.

• The cohort studies had a long follow-up period of 11.0-14.0 years.

• A weakness may be the small number of studies analyzed.

## Introduction

Coronary heart disease (CHD) is a major cause of death and disability worldwide (1). Advanced obstructive CHD can exist in patients with minimal or no symptoms and can progress rapidly (2), so early detection is extremely important. Many clinicians carry out screening for asymptomatic CHD and participants in wellness programs often also request such screening, but the usefulness of CHD screening is yet to be confirmed. It was reported that the incidence of CHD was not significantly reduced in asymptomatic diabetic patients when screening was conducted by myocardial scintigraphy (3), and it was also reported that coronary CT screening of asymptomatic patients without a history of coronary artery disease fails to prevent major cardiovascular events (4).

Male pattern baldness, also called androgenetic alopecia (AGA), is the most common cause of hair loss. It affects approximately 30 to 40% of adult men (5) and it is seen in 80% of men by the age of 80 years (6). AGA is considered to be a heritable, androgen-dependent condition that is characterized by varying degrees of thinning/hair loss primarily at the vertex and the frontal areas (temples) of the scalp. In men with AGA, the thin residual hairs tend to be of various lengths and diameters since each follicle is in a different phase of the hair cycle, so the presence of variations in hair length and texture is a classic feature of thin condition (7).

Several recent studies have shown that baldness is associated with the risk of coronary heart disease (CHD)(8-13). These studies have generally found a positive relation between baldness and CHD,

1  
2  
3  
4  
5  
6 although the strength of the association has varied.  
7  
8

9 Clarifying the relationship between baldness and CHD could lead to more effective approaches to  
10  
11 the early detection of heart disease, since it might permit the reliable identification of persons with  
12  
13 an increased risk of suffering from a cardiac event and allow the delivery of appropriate therapy (e.g.,  
14  
15 antihypertensive or lipid-lowering therapy) to improve the prognosis of such high-risk persons.  
16  
17 Accordingly, we performed a meta-analysis to further assess the influence of male pattern baldness  
18  
19 (AGA) on CHD.  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **Methods**

### 30 *Search strategy*

31  
32 The Medline and Cochrane Library electronic databases were searched from 1950 until November  
33  
34 27, 2012 using the medical subject headings “Baldness” (“baldness” or “hair loss” or “alopecia”)  
35  
36 and “Coronary heart disease” (“coronary heart disease” or “cardiovascular disease” or “coronary  
37  
38 artery disease”) to identify observational studies that tested the association between baldness and  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
CHD. The reference lists of all relevant studies were also reviewed.

### 59 *Study selection*

60 We performed initial screening based on the study titles or abstracts, while the second screening

1  
2  
3  
4  
5  
6 involved full-text review. Cohort studies, case-control studies, and cross-sectional studies that  
7  
8  
9 assessed the relation between male pattern baldness and CHD were eligible for inclusion if the  
10  
11  
12 following criteria were met: 1) the full text of the report was published in English, 2) the relative risk  
13  
14 (risk ratio, hazard ratio, or odds ratio) was reported with adjustment for possible confounders (e.g.  
15  
16 age, smoking, family history of baldness, or family history of CHD), 3) the presence and severity of  
17  
18 male pattern baldness was reported, and 4) CHD events were reported.  
19  
20  
21  
22  
23  
24  
25

### 26 *Definitions of baldness and CHD*

27  
28  
29 Baldness was defined according to the description in the history and/or on the basis of terms such  
30  
31 as AGA and male pattern hair loss. We excluded studies that analyzed men with other types of  
32  
33 baldness (e.g., alopecia areata or scarring alopecia). CHD was defined as including all of the  
34  
35 following: coronary artery disease, myocardial infarction, angina pectoris, cardiomyopathy, and  
36  
37 other types of ischemic heart disease.  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 *Assessment of validity*

48  
49 To ascertain the validity of the eligible studies, the quality of each report was appraised with  
50  
51 reference to the STROBE statement (14). Moreover, the Newcastle-Ottawa Scale for assessing  
52  
53 quality of nonrandomized studies in meta-analyses was used to quantify the validity of each study  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 (15).  
7  
8  
9  
10

### 11 *Data extraction*

12  
13  
14  
15 Two investigators (T.Y. and K.H.) independently reviewed each study to determine its eligibility,  
16  
17 and then extracted and tabulated all of the relevant data. Disagreement was resolved by consensus  
18  
19 between the two investigators.  
20  
21

22  
23 The following information was obtained from each study: first author, year of publication, type of  
24  
25 study, country, number of subjects, CHD events, method of assessing baldness, follow-up period,  
26  
27 mean age, smoking, covariates used for adjustment during analysis, and severity of baldness.  
28  
29  
30  
31  
32  
33  
34

### 35 *Statistical analysis*

36  
37  
38 The pooled relative risk (RR) adjusted for possible confounders and its 95% confidence interval  
39  
40 (CI) were calculated for the risk of CHD events in each study by the DerSimonian-Laird random  
41  
42 effect model weighted with inverse variance. Equivalence of RRs between the cohort studies and the  
43  
44 cross-sectional studies was assessed by the z-statistic test. Cochrane's  $\chi^2$  test and the  $I^2$  test were  
45  
46 used to evaluate heterogeneity among studies and a threshold P value of 0.10 was considered to be  
47  
48 significant (16). Possible publication bias was evaluated by creating a funnel plot of the effect size  
49  
50  
51  
52  
53  
54  
55 for each study versus the standard error (SE). Funnel plot asymmetry was assessed by the Begg and  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Egger tests. All statistical analyses were performed with Stata 12.0 software (StataCorp, College  
7  
8  
9 Station, TX). Results are expressed as the mean with 95%CI, unless otherwise indicated. Except for  
10  
11 tests of heterogeneity, a P value of less than 0.05 was considered significant. All procedures were  
12  
13 performed in accordance with the guideline published by the Meta-analysis Of Observational  
14  
15 Studies in Epidemiology (MOOSE) group (17) and the PRISMA statement (18)(**Supplementary**  
16  
17  
18 **Data 1**).

## 21 22 23 24 25 26 **Results**

### 27 28 29 *Literature search*

30  
31  
32 **Figure 1** shows a flow chart of the study selection process. We identified a total of 850 reports by  
33  
34 searching the databases. Among these, 834 reports were excluded after review of the title and  
35  
36 abstract, leaving 16 studies for further evaluation. Ten of these 16 studies were excluded after full  
37  
38 text evaluation, chiefly because of the lack of pertinent data. The remaining 6 studies (8-13) fulfilled  
39  
40 the inclusion criteria were used for this meta-analysis.  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 51 *Study characteristics*

52  
53 The 6 studies that were selected included 3 cohort studies and 3 case-control studies, and their  
54  
55 characteristics are summarized in **Table 1**. There were moderate differences with respect to the  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 country of origin, number of subjects, and method of assessing baldness. The studies were published  
7  
8  
9 between 1993 and 2008. Four studies (9-11,13) were conducted in the USA and the other 2 (8,12)  
10  
11 were performed in the European Union. The size of the study populations ranged from 1,437 to  
12  
13 19,112 subjects (mean: 6,165 subjects). In 5 of the 6 studies (8,10-13), CHD was defined as  
14  
15 non-fatal myocardial infarction. The mean follow-up period ranged from 11 to 14 years. The method  
16  
17 of assessing baldness varied, with a modified or simplified Hamilton scale being employed in 4  
18  
19 studies (8,10,11,13) and a personal scale being used in the other 2 studies (9,12).  
20  
21  
22  
23  
24

25  
26 Three studies (10,11,13) used a modified Hamilton scale that reduced the 12 categories of the  
27  
28 original scale to the following five: no baldness (I, II); frontal baldness alone (IIa, III, IIIa, IVa); mild  
29  
30 vertex baldness (III vertex, IV); moderate vertex baldness (V, Va); and severe vertex baldness (VI,  
31  
32 VII). One study (8) used a simplified Hamilton scale, in which the extent of baldness was classified  
33  
34 as follows: none; frontoparietal region (no bald triangle but >3 cm in front of the ear, or bald triangle  
35  
36 but ≤3 cm in front of the ear); crown-top region (thick hair, partly thin hair, bald spot, or bald top  
37  
38 and front); and combined.  
39  
40  
41  
42  
43  
44

45  
46 Among the two studies that employed personal scales, Ford, classified baldness as none,  
47  
48 minimum, moderate, or severe (9). Minimum baldness corresponded to no obvious baldness when  
49  
50 the participant walked into the examining room, while moderate baldness was observable baldness at  
51  
52 the first encounter and severe baldness was obvious at the first encounter. In the other study, Miric  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 classified baldness as none, frontal, parietal (vertex), or combined (12).  
7

8  
9 The RR for CHD of the subjects with baldness was adjusted for several coronary risk factors (age,  
10  
11 smoking, diabetes, etc.) in each study, but the number of variables differed significantly among the  
12  
13 studies.  
14  
15

16  
17 The reports on all 3 cross-sectional studies (11-13) explicitly mentioned the limitations of a  
18  
19 cross-sectional design (i.e., it cannot assess causality), the possible biases of each study, and the  
20  
21 influence of confounders. The reports on all 3 cohort studies (8-10) mentioned the possibility of  
22  
23 misclassification of the severity of baldness.  
24  
25  
26  
27

28  
29 One study found that baldness was not associated with CHD (13), but the other 5 studies  
30  
31 concluded that baldness was associated with a significantly increased risk of CHD, although the  
32  
33 strength of the association varied.  
34  
35  
36  
37

38 According to the Newcastle-Ottawa quality assessment scale for observational studies, all of the  
39  
40 studies used in this meta-analysis achieved at least six out of nine points, indicating that the overall  
41  
42 quality of the studies was good (**Supplementary Data 2**).  
43  
44  
45  
46  
47

#### 48 49 *Association of baldness with CHD*

50  
51 Among the 6 studies with a total of 36,990 subjects that were selected (8-13), no study showed a  
52  
53 significant decrease in the risk of CHD for men with baldness.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 **Figures 2-4** show the results obtained by combining the RRs for CHD with the random-effect  
7  
8 model.

9  
10  
11 In the 3 cohort studies (8-10), the adjusted RR of CHD for men of all ages with severe baldness  
12  
13 versus those without baldness was 1.32 (95%CI: 1.08-1.63; P=0.008; P for heterogeneity=0.26; I  
14  
15 squared=25%). Analysis restricted to younger subjects (<55 years old or ≤60 years old at baseline)  
16  
17 revealed a similar association of severe baldness with CHD (RR 1.44 (95%CI: 1.11-1.86; P=0.006; P  
18  
19 for heterogeneity=0.59; I squared=0%)) (**Figure 2**).

20  
21 In the 3 case-control studies (11-13), the adjusted RR was 1.70 (95%CI: 1.05-2.74; P=0.03; P for  
22  
23 heterogeneity=0.01; I squared=78%) for all subjects, while the RR was 1.84 (95%CI: 1.30-2.62;  
24  
25 P=0.001; P for heterogeneity=0.17; I squared=44%) among the younger subjects (**Figure 3**). The  
26  
27 difference of RR values between the cohort and case-control studies was not significant (all subjects:  
28  
29 P=0.15; patients≤60 years old: P=0.07).

### 30 31 32 *Stratified analysis*

33  
34 All three studies that assessed the severity of baldness by using the modified Hamilton scale  
35  
36 (10,11,13) showed that vertex baldness was associated with CHD and that this association was  
37  
38 dependent on the severity of baldness. In subjects with severe vertex baldness, the RR was 1.48  
39  
40 (95%CI: 1.04-2.11; P=0.03; P for heterogeneity=0.02; I squared=75%), while the RR was 1.36  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(95%CI: 1.16-1.58; P<0.001; P for heterogeneity=0.95; I squared=0%) for moderate vertex baldness and 1.18 (95%CI: 1.04-1.35; P<0.001; P for heterogeneity=0.35; I squared=4%) for mild vertex baldness. In contrast, there was no significant association of frontal baldness with CHD and the RR was only 1.11 (95%CI: 0.92-1.32; P=0.28; P for heterogeneity=0.24; I squared=30%) (**Figure 4**).

Because the method of assessing baldness was not homogenous, we also performed a sensitivity analysis of the studies that used personal scales to classify baldness into 4 grades (none, frontal, crown-top, or combined) (8,12). Similar results were obtained showing that the association with CHD depended on the severity of baldness, with an RR of 1.69 (95%CI: 1.28-2.23; P<0.001; P for heterogeneity=0.97; I squared=0%) for combined baldness, an RR of 1.52 (95%CI: 0.97-2.39; P=0.07; P for heterogeneity=0.001; I squared=91%) for crown-top baldness, and an RR of 1.22 (95%CI: 0.70-2.14; P=0.49; P for heterogeneity=0.05; I squared=73%) for frontal baldness.

### ***Publication bias***

The funnel plot, Begg's test, and Egger's test were used to evaluate the potential influence of publication bias on the association between baldness and CHD. The funnel plot did not show an asymmetric pattern, while Egger's test and Begg's test revealed no significant publication bias (all  $P \geq 0.05$ ).

## Discussion

The present meta-analysis of 6 studies from the USA and Europe demonstrated that vertex baldness was associated with an increased risk of CHD among subjects of all ages and also among younger men. Interestingly, frontal baldness was not associated with CHD.

When baldness was classified by the Hamilton-Norwood scale, which is the most commonly used classification of male pattern baldness worldwide (19), the relation of CHD with baldness was shown to be dependent on the severity of baldness.

These findings support the hypothesis that vertex baldness is a local manifestation of factors promoting systemic atherosclerosis, such as metabolic syndrome, hypertension, and smoking.

Minoxidil (Rogaine) is one of the most popular drugs for the treatment of male pattern baldness. Minoxidil was originally developed as an antihypertensive agent (vasodilator) and it is thought to improve the blood flow and the supply of oxygen and nutrients to the hair follicles by dilating vessels in the scalp and opening potassium channels. This may lead to shedding of hairs in the telogen phase, which are then replaced by thicker hairs in the anagen phase (20).

Minoxidil is only indicated for vertex baldness and is ineffective for frontal baldness (21), which supports our finding that vertex baldness is more closely related to atherosclerosis than frontal baldness.

### *Mechanism of the relation between baldness and CHD*

The reason for the association between baldness and CHD is unclear. It has been suggested that classical coronary risk factors (e.g., age, hypertension, dislipidemia, and smoking) might influence both conditions, so that baldness is a marker of atherosclerosis. In fact, previous studies have demonstrated a positive association between male pattern baldness and insulin resistance (22), metabolic syndrome (23), and hypertension (24). It has also been postulated that baldness is linked to CHD by mechanisms such as hyperinsulinemia, chronic inflammation, and increased peripheral sensitivity to androgens, and these are briefly discussed below.

1) Hyperinsulinemia/insulin resistance is the central factor in metabolic syndrome and it promotes intolerance of carbohydrates and the development of central (abdominal) obesity. Insulin resistance has also been shown to cause vasoconstriction and impairs the supply of nutrients to the hair follicles of the scalp, as well as enhancing the influence of dihydro-testosterone (DHT) on follicular miniaturization (25,26).

2) A proinflammatory state could increase the levels of inflammatory cytokines in the arterial walls (27) and hair follicles (28). High-sensitivity C-reactive protein is a marker of inflammation and is also a good predictor of future cardiovascular disease (29), so chronic inflammation could be related to both CHD and baldness.

3) Male pattern baldness may be caused by increased peripheral sensitivity to androgens, since bald



1  
2  
3  
4  
5  
6 men show an increase of androgen receptors in the scalp (30) and have higher serum levels of both  
7  
8  
9 total and free testosterone (31). Free testosterone is converted to DHT by 5 $\alpha$ -reductase, leading to  
10  
11  
12 miniaturization of hair follicles. It has been reported that 5 $\alpha$ -reductase exists in the blood vessels and  
13  
14  
15 the heart, as does the DHT receptor, which is involved in vascular smooth muscle proliferation that  
16  
17  
18 represents a fundamental feature of arteriosclerosis along with the deposition of lipids (32).  
19

### 20 21 22 23 ***Strengths and Limitations*** 24

25  
26 The strengths of this meta-analysis were as follows. First, our analysis included several large cohort  
27  
28 and case-control studies, with a total of 36,990 subjects. Second, the cohort studies had a long  
29  
30 follow-up period (11.0-14.0 years). In all of the studies, analyses were adjusted for various classical  
31  
32 coronary risk factors, such as age, smoking, hypertension, dyslipidemia, and body mass index.  
33  
34

35  
36 However, this meta-analysis also had several limitations. First, we only reviewed English-language  
37  
38 reports, which could have led to selection bias. Our analyses of publication bias did not suggest that  
39  
40 unpublished results had been missed, but these analyses might have been underpowered due to the  
41  
42 small effect sizes. Second, although most factors showed no significant between-study heterogeneity,  
43  
44  
45 it was significant for some factors, suggesting that differences of epidemiological characteristics  
46  
47 (e.g., the rate of severe baldness or CHD) or different diagnostic criteria (for baldness and/or CHD)  
48  
49  
50 contributed to heterogeneity to some extent.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Unlike the results of the other studies, the effect sizes reported by Lesko (11) varied widely and even  
7  
8  
9 changed the sign when different patterns of baldness were compared (Fig. 4). This study had the  
10  
11  
12 lowest validity score (6/9 points on the Newcastle-Ottawa scale) among the six studies included in  
13  
14  
15 our meta-analysis (**Supplementary Data 2**). Lesko et al. contacted the coronary care units of  
16  
17  
18 participating hospitals to identify potential subjects with their first myocardial infarction and to  
19  
20  
21 obtain permission to conduct an interview. Thus, details about CHD were not obtained in this  
22  
23  
24 study, which might have led to bias and influenced the effect size.

25  
26 Moreover, as already reported by Rebora et al. (33), Lotufo et al. (10) relied on each patient's  
27  
28  
29 memory of a condition that had developed up to 40 years before, which might have led to recall bias.  
30  
31  
32 These two studies would have a higher risk of misclassification bias that could lead to  
33  
34  
35 underestimating the strength of the association between baldness and CHD, since it is often  
36  
37  
38 considered shameful to admit to the existence of baldness.

39  
40  
41 The third limitation was incomplete information about the use of medications such as anticoagulants,  
42  
43  
44 anticonvulsants, beta-blockers, antidepressants, and hormone replacement therapy that may have  
45  
46  
47 contributed to baldness (34).

48  
49  
50 Fourth, the methods used to assess baldness varied between studies, which meant that we could not  
51  
52  
53 rule out other local causes of diffuse hair loss (alopecia areata or nonscarring alopecia), as well as  
54  
55  
56 possible systemic causes (e.g., thyroiditis, iron deficiency (35,36), trauma, excessive dieting, or  
57  
58  
59

1  
2  
3  
4  
5  
6 debilitating diseases).

7  
8  
9 Even with such limitations, the present meta-analysis provided useful evidence regarding the  
10  
11 potential influence of baldness on CHD. Patients and physicians should consider the possibility that  
12  
13 baldness is associated with an increased risk of CHD.  
14  
15  
16  
17  
18  
19

### 20 *Conclusions*

21  
22  
23 In the present meta-analysis, vertex baldness was associated with an increased risk of CHD among  
24  
25 younger men as well as among all subjects, and the relation was dependent on the severity of  
26  
27 baldness. These findings suggest that vertex baldness is more closely associated with systemic  
28  
29 atherosclerosis than frontal baldness. Thus, cardiovascular risk factors should be reviewed carefully  
30  
31 in men with vertex baldness, especially younger men, and they should be encouraged to improve  
32  
33 their cardiovascular risk profile.  
34  
35  
36  
37  
38  
39

40  
41 In addition, the relationship between baldness and CHD should be investigated by further studies,  
42  
43 including well-designed and controlled cohort studies, in order to confirm whether persons with  
44  
45 male pattern baldness (especially severe vertex baldness) have an increased risk of CHD.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### ***Contributors***

TY, KH and TK conceived the idea of the study and were responsible for the design of the study. TY and KH were responsible for undertaking for the data analysis and produced the tables and figures. TY and KH provided input into the data analysis. The initial draft of the manuscript was prepared by TY and KH and then circulated repeatedly among all authors for critical revision. TY was responsible for the acquisition of the data and TY, KH and TK contributed to the interpretation of the results.

### ***Copyright/licence for publication***

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd. and its Licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJ PGL products and sublicences to exploit all subsidiary rights, as set out in our licence (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).

### ***Competing Interests***

All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare:

1  
2  
3  
4  
5  
6 no support from any organisation for the submitted work; no financial relationships with any  
7  
8  
9 organisations that might have an interest in the submitted work in the previous three years; no other  
10  
11  
12 relationships or activities that could appear to have influenced the submitted work.  
13

14  
15 ***Ethical approval***

16  
17 Not needed.  
18  
19

20  
21 ***Funding statement***

22  
23 This research received no specific grant from any funding agency in the public, commercial or  
24  
25 not-for-profit sectors.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 ***Supplementary Data***

36  
37  
38 **Supplementary Data 1. PRISMA Checklist.**

39  
40  
41 **Supplementary Data 2. Newcastle-Ottawa quality assessment scale for observational studies**  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Lopez AD, Mathers CD, Ezzati M, *et al.* Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;367:1747-57.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J* 1986;111:383-90.
3. Young LH, Wackers FJ, Chyun DA, *et al.*; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301:1547-55.
4. McEvoy JW, Blaha MJ, Nasir K, *et al.* Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population. *Arch Intern Med* 2011;171:1260-8.
5. Olsen EA. Androgenetic alopecia. In: Olsen EA ed. *Disorders of Hair Growth: Diagnosis and Treatment*. New York, NY: McGraw-Hill; 1994:257-83.
6. Hamilton JB. Patterned loss of hair in man; types and incidence. *Ann N Y Acad Sci* 1951;53:708-28.
7. Price VH. Treatment of hair loss. *N Engl J Med* 1999;341:964-73.
8. Schnohr P, Lange P, Nyboe J, *et al.* Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. *Am Heart J* 1995;130:1003-10.

- 1  
2  
3  
4  
5  
6 9. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men.  
7  
8  
9 Am J Epidemiol 1996;143:651-7.  
10  
11  
12 10. Lotufo PA, Chae CU, Ajani UA, *et al.* Male pattern baldness and coronary heart disease: the  
13  
14 Physicians' Health Study. Arch Intern Med 2000;160:165-71.  
15  
16  
17 11. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial  
18  
19 infarction in men. JAMA 1993;269:998-1003.  
20  
21  
22 12. Mirić D, Fabijanić D, Giunio L, *et al.* Dermatological indicators of coronary risk: a case-control  
23  
24 study. Int J Cardiol 1998;67:251-5.  
25  
26  
27 13. Shahar E, Heiss G, Rosamond WD, *et al.* Baldness and myocardial infarction in men: the  
28  
29 atherosclerosis risk in communities study. Am J Epidemiol 2008;167:676-83.  
30  
31  
32 14. von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational  
33  
34 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin  
35  
36 Epidemiol 2008;61:344-9.  
37  
38  
39 15. Wells G, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the  
40  
41 quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute.  
42  
43 Available from [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed 4  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*  
7  
8  
9 2002;21:1539-58.  
10  
11  
12 17. Stroup DF, Berlin JA, Morton SC, *et al.* Meta-analysis of observational studies in epidemiology:  
13  
14 a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.  
15  
16 *JAMA* 2000;283:2008-12.  
17  
18  
19 18. Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews  
20  
21 and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.  
22  
23  
24  
25  
26 *Ann Intern Med* 2009;151:W65-94.  
27  
28  
29 19. Norwood OT. Male pattern baldness: classification and incidence. *South Med J*  
30  
31  
32 1975;68:1359-65.  
33  
34  
35 20. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. *Br J Dermatol*  
36  
37  
38 2004;150:186-94.  
39  
40  
41 21. Scow DT, Nolte RS, Shaughnessy AF. Medical treatments for balding in men. *Am Fam*  
42  
43 *Physician* 1999;59:2189-94.  
44  
45  
46 22. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic  
47  
48 syndrome in male patients with early-onset androgenetic alopecia. *Eur J Dermatol* 2011;21:79-82.  
49  
50  
51 23. Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: a  
52  
53 community-based survey. *Br J Dermatol* 2010;163:371-7.  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6 24. Ahouansou S, Le Toumelin P, Crickx B, *et al.* Association of androgenetic alopecia and  
7  
8 hypertension. *Eur J Dermatol* 2007;17:220-2.  
9  
10  
11 25. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of  
12  
13 insulin resistance. *Lancet* 2000;356:1165-6.  
14  
15  
16 26. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, *et al.* Male androgenetic  
17  
18 alopecia and cardiovascular risk factors: A case-control study. *Actas Dermosifiliogr*  
19  
20  
21  
22 2010;101:248-56.  
23  
24  
25 27. Yudkin JS, Stehouwer CD, Emeis JJ, *et al.* C-reactive protein in healthy subjects: associations  
26  
27  
28 with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines  
29  
30  
31 originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999;19:972-8.  
32  
33  
34 28. Hirso P, Rajala U, Hiltunen L, *et al.* Obesity and low-grade inflammation among young Finnish  
35  
36  
37 men with early-onset alopecia. *Dermatology* 2007;214:125-9.  
38  
39  
40 29. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and  
41  
42  
43 prevention. *Circulation* 2003;107:363-9.  
44  
45  
46 30. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher  
47  
48  
49 levels of androgen receptors than those from non-balding scalp. *J Endocrinol* 1998;156:59-65.  
50  
51  
52 31. Demark-Wahnefried W, Lesko SM, Conaway MR, *et al.* Serum androgens: associations with  
53  
54  
55 prostate cancer risk and hair patterning. *J Androl* 1997;18:495-500.  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 32. Fujimoto R, Morimoto I, Morita E, *et al.* Androgen receptors, 5alpha-reductase activity and  
7  
8  
9 androgen-dependent proliferation of vascular smooth muscle cells. *J Steroid Biochem Mol Biol*  
10  
11  
12 1994;50:169-74.  
13  
14 33. Rebora A. Baldness and coronary artery disease: the dermatologic point of view of a  
15  
16  
17 controversial issue. *Arch Dermatol* 2001;137:943-7.  
18  
19  
20 34. Llau ME, Viraben R, Montastruc JL. [Drug-induced alopecia: review of the literature]. *Therapie*  
21  
22  
23 1995;50:145-50.  
24  
25  
26 35. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its  
27  
28  
29 potential relationship to hair loss. *J Am Acad Dermatol* 2006;54:824-44.  
30  
31  
32 36. Olsen EA. Iron deficiency and hair loss: the jury is still out. *J Am Acad Dermatol* 2006;54:903-6.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 **Figure legends**  
7

8  
9 **Figure 1. Flow diagram of study selection.**

10  
11  
12 **Figure 2. Association of baldness with CHD in the 3 cohort studies.**

13  
14 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
15 disease (CHD). CI=confidence interval; RR=relative risk.  
16  
17  
18

19  
20  
21 **Figure 3. Association of baldness with CHD in the 3 case-control studies.**

22  
23 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
24 disease (CHD). CI=confidence interval; RR=relative risk.  
25  
26  
27

28  
29 **Figure 4. Association of baldness with CHD in studies using the modified Hamilton scale.**

30  
31 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
32 disease (CHD). CI=confidence interval; RR=relative risk  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Summary of studies evaluating the association between baldness and coronary heart disease

First author, year	Type of study	Country	Subjects	CHD (events)	Assessment of baldness	Follow-up (years)	Covariates used for adjustment
Schnohr, 1995 (8)	Cohort	Denmark	5837	Myocardial infarction (750)	Simplified Hamilton (None, Frontoparietal, Crown-top, Combined)	12.0	Age, smoking, systolic blood pressure, cholesterol, triglycerides, physical activity, BMI, family history of MI, marital status, education, economic status, diabetes, and alcohol consumption
Ford, 1996 (9)	Cohort	USA	3994	Ischemic heart disease (965)	Personal scale (None, Minimum, Moderate, Severe)	14.0	Age, age squared, race, education, systolic blood pressure, antihypertensive medication, cholesterol, smoking, BMI, and diabetes mellitus
Lotufo, 2000 (10)	Cohort	USA	19112	Nonfatal MI, angina, coronary revascularization (1446)	Modified Hamilton (None, Frontal, Mild vertex, Moderate vertex, Severe vertex)	11.0	Age, aspirin assignment, beta carotene assignment, BMI, height (cm), hypertension, hypercholesterolemia, diabetes, parental history of MI, physical activity, smoking, and alcohol use.

1	Lesko,	Case-	USA	1437	Non-fatal	Modified Hamilton (None,	-	Age, race, religion, years of education, BMI, use of
2								
3								
4	1993 (11)	control			Myocardial	Frontal only, Mild vertex,		alcohol and cigarettes, family history of myocardial
5								
6					infarction (665)	Moderate vertex, Severe vertex)		infarction, personal history of angina, hypertension,
7								
8								diabetes, hypercholesterolemia, gout, exercise,
9								
10								personality, and number of doctor visits in the past year.
11								
12								
13	Miric,	Case-	Croatia	1554	Non-fatal	Personal score ( None, Any,	-	Age, family history of MI, hypertension,
14								
15	1998 (12)	control			Myocardial	Frontal, Parietal, Fronto-parietal)		hypercholesterolemia, BMI, diabetes, and smoking.
16								
17					infarction (842)			
18								
19								
20	Shahar,	Case-	USA	5056	Non-fatal	Modified Hamilton ( None,	-	Age, smoking, BMI, race-center, cholesterol-lowering
21								
22	2008 (13)	control			Myocardial	Frontal, Mild vertex, Moderate		medication, antihypertensive medication, HDL,
23								
24					infarction (767)	vertex, Severe vertex)		diabetes, educational level, and family history of MI.
25								
26								

CHD, coronary heart disease; BMI, body mass index; MI, myocardial infarction; AGA, androgenic alopecia; HDL, high density lipoprotein;




Fig. 2






Fig. 3



BMJ Open: first published as 10.1136/bmjopen-2012-002537 on 3 April 2013. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.



Fig. 4



BMJ Open: first published as 10.1136/bmjopen-2012-002537 on 3 April 2013. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	7-8

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Page 1 of 2



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7-8
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9, Fig 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9, Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-10, Table 1, Fig 2-4
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-12, Fig 2-4
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10-12 Suppl.2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11-13
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19-20



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Supplementary Data 2. Newcastle-Ottawa quality assessment scale for observational studies

Study reference (author, year)	Selection	Comparability	Outcome/Exposure
Cohort studies			
Schnohor, 1995 (8)	***	**	***
Ford, 1996 (9)	***	**	***
Lotufo, 2000 (10)	***	**	***
Case-control studies			
Lesko, 1993 (11)	**	**	**
Miric, 1998 (12)	***	**	**
Shahar, 2008 (13)	****	**	**

For peer review only



## Male Pattern Baldness and Its Association with Coronary Heart Disease: A Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002537.R1
Article Type:	Research
Date Submitted by the Author:	08-Feb-2013
Complete List of Authors:	Yamada, Tomohide; University of Tokyo, Department of Diabetes and Metabolic Diseases Hara, Kazuo; University of Tokyo, Department of Diabetes and Metabolic Diseases Umematsu, Hitomi; University of Tokyo, Department of Diabetes and Metabolic Diseases Kadowaki, Takashi; University of Tokyo, Department of Diabetes and Metabolic Diseases
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Cardiovascular medicine, Diabetes and endocrinology, Diagnostics, Epidemiology, Health economics
Keywords:	Coronary heart disease < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, Adult dermatology < DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

only

1  
2  
3  
4  
5  
6 **Male Pattern Baldness and Its Association with Coronary Heart Disease: A Meta-Analysis**  
7

8  
9 Tomohide Yamada, MD

10  
11 Kazuo Hara, MD, PhD\*

12  
13 Hitomi Umematsu, MD

14  
15  
16  
17 Takashi Kadowaki, MD, PhD

18  
19  
20 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine

21  
22 University of Tokyo, Japan

23  
24  
25  
26 \* Corresponding author

27  
28  
29 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan

30  
31  
32 Tel.: +81-3-5800-8818; Fax: +81-3-5689-7209

33  
34  
35 E-mail address: [haratky@gmail.com](mailto:haratky@gmail.com)

36  
37  
38  
39  
40 **Brief title:** Male pattern baldness and CHD

41  
42  
43  
44  
45  
46 **Word count:** 3691 words

**Abstract****Objective:**

To confirm the association between male pattern baldness and coronary heart disease (CHD).

**Design:**

Meta-analysis of observational studies.

**Data sources:**

Medline and the Cochrane Library were searched for articles published up to November 2012 using keywords that included both 'baldness' and 'coronary heart disease' and the reference lists of those studies identified were also searched.

**Study selection:**

Observational studies were identified that reported risk estimates for CHD related to baldness. Two observers independently assessed eligibility, extracted data, and assessed the possibility of bias.

**Data synthesis:**

The adjusted relative risk (RR) and 95% confidence interval (95%CI) were estimated using the DerSimonian-Laird random-effect model.

**Results:**

Included 850 possible studies, three cohort studies and three case-control studies were selected (36,990 subjects).



1  
2  
3  
4  
5  
6 In the cohort studies, the adjusted RR of men with severe baldness for CHD was 1.32 (95%CI: 1.08 -  
7  
8  
9 1.63,  $P = 0.008$ ,  $I^2 = 25\%$ ) versus those without baldness. Analysis of younger men (<55 or ≤60  
10  
11  
12 years) showed a similar association of CHD with severe baldness (RR: 1.44, 95%CI: 1.11 - 1.86,  $P =$   
13  
14 0.006,  $I^2 = 0\%$ ).

15  
16  
17 In 3 studies employing the modified Hamilton scale, vertex baldness was associated with CHD and  
18  
19  
20 the relation depended on the severity of baldness (severe vertex: RR 1.48 (1.04 - 2.11,  $P = 0.03$ );  
21  
22 moderate vertex: RR 1.36 (1.16 - 1.58,  $P < 0.001$ ); mild vertex: RR 1.18 (1.04 - 1.35,  $P < 0.001$ ).  
23  
24  
25 However, frontal baldness was not associated with CHD (RR 1.11 (0.92 - 1.32,  $P = 0.28$ )).  
26  
27

#### 28 29 **Conclusion:**

30  
31  
32 Vertex baldness, but not frontal baldness, is associated with an increased risk of CHD. The  
33  
34  
35 association with CHD depends on the severity of vertex baldness and also exists among younger  
36  
37  
38 men. Thus, vertex baldness might be more closely related to atherosclerosis than frontal baldness,  
39  
40  
41 but the association between male pattern baldness and CHD deserves further investigation.  
42  
43  
44

45  
46  
47 **Key words:** male pattern baldness, androgenetic alopecia, coronary heart disease, cardiovascular  
48  
49  
50 disease, relative risk, meta-analysis  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article summary

### Article focus:

• The present meta-analysis aimed to confirm the association of male pattern baldness (androgenetic alopecia) with an increased risk of coronary heart disease (CHD).

### Key messages:

• Meta-analysis of 6 observational studies with a total of 36,690 subjects showed that vertex baldness is associated with an increased risk of CHD and that the relationship depends upon the severity of baldness, while frontal baldness is not.

• Thus, vertex baldness might be a marker of CHD and is more closely associated with systemic atherosclerosis than frontal baldness.

• This potential relationship should be investigated in further studies, including well-designed prospective studies.

### Strengths and limitations of this study:

• This was the first meta-analysis of the association between baldness and CHD; it showed that the relationship depends on the severity of baldness.

• The cohort studies had a long follow-up period of 11.0 - 14.0 years.

• A weakness might be the small number of studies analyzed.

## Introduction

Coronary heart disease (CHD) is a major cause of death and disability worldwide (1). Advanced obstructive CHD can exist in patients with minimal or no symptoms and can progress rapidly (2), so early detection is extremely important. Many clinicians carry out screening for asymptomatic CHD and participants in wellbeing programs often also request such screening, but the usefulness of CHD screening has yet to be confirmed. Young et al. (2009) reported that the incidence of CHD was not significantly reduced in asymptomatic diabetic patients when screening was conducted by myocardial scintigraphy (3), and McEvoy et al. (2011) also reported that coronary computed tomography screening of asymptomatic patients without a history of coronary artery disease fails to prevent major cardiovascular events (4).

Male pattern baldness, also called androgenetic alopecia (AGA), is the most common cause of hair loss. It affects approximately 30 to 40% of adult men (5) and it is seen in 80% of men by the age of 80 years (6). AGA is considered to be a heritable, androgen-dependent condition that is characterized by varying degrees of thinning/hair loss primarily at the vertex and the frontal areas (temples) of the scalp. In men with AGA, the thin residual hairs tend to be of various lengths and diameters since each follicle is in a different phase of the hair cycle, so the presence of variations in hair length and texture is a classic feature of this thinning condition (7).

Several recent studies have shown that baldness is associated with the risk of CHD (8-12). These

1  
2  
3  
4  
5  
6 studies have generally found a positive association between baldness and CHD, although the  
7  
8  
9 strength of the association has varied (8-13).

10  
11 Clarifying the relationship between baldness and CHD could lead to more effective approaches to  
12  
13 the early detection of heart disease, since it might permit the reliable identification of persons with  
14  
15 an increased risk of suffering from a cardiac event thereby allowing the delivery of appropriate  
16  
17 therapy (e.g., antihypertensive or lipid-lowering therapy) to improve the prognosis of such high-risk  
18  
19 persons. Accordingly, we performed a meta-analysis to further assess the influence of male pattern  
20  
21 baldness (AGA) on CHD.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 **Methods**

### 33 *Search strategy*

34  
35  
36  
37 The Medline and Cochrane Library electronic databases were searched from January 1, 1950 until  
38  
39 November 27, 2012 using the medical subject headings “Baldness” (“baldness” or “hair loss” or  
40  
41 “alopecia”) and “Coronary heart disease” (“coronary heart disease” or “cardiovascular disease” or  
42  
43 “coronary artery disease”) to identify observational studies that estimated the association between  
44  
45 baldness and CHD. The reference lists of all studies identified were also reviewed.  
46  
47  
48  
49  
50  
51

### 52 *Study selection*

1  
2  
3  
4  
5  
6 We performed initial screening based on the study titles or abstracts, while the second screening  
7  
8  
9 involved a full-text review. Cohort studies, case-control studies, and cross-sectional studies that  
10  
11  
12 assessed the association between male pattern baldness and CHD were eligible for inclusion if the  
13  
14  
15 following criteria were met: 1) the full text of the report was published in English, 2) the relative risk  
16  
17  
18 (risk ratio, hazard ratio, or odds ratio) was reported with adjustment for possible covariates (e.g. age,  
19  
20  
21 smoking, family history of baldness, or family history of CHD), 3) the presence and severity of male  
22  
23  
24 pattern baldness was reported, and 4) CHD events were reported.  
25  
26  
27  
28

### 29 *Definitions of baldness and CHD*

30  
31  
32 Baldness was defined according to the description in the history and/or on the basis of terms such  
33  
34  
35 as AGA and male pattern hair loss. We excluded studies that analyzed men with other types of  
36  
37  
38 baldness (e.g., alopecia areata or scarring alopecia). CHD was defined as including all of the  
39  
40  
41 following: coronary artery disease, myocardial infarction, angina pectoris, cardiomyopathy, and  
42  
43  
44 other types of ischemic heart disease.  
45  
46  
47  
48

### 49 *Assessment of validity*

50  
51  
52 To ascertain the validity of the eligible studies, the quality of each report was appraised with  
53  
54  
55 reference to the STROBE statement (14). Moreover, the Newcastle-Ottawa Scale for assessing  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 quality of non-randomized studies in meta-analyses was used to quantify the validity of each study  
7  
8  
9 (15).

### 10 11 12 13 14 15 **Data extraction**

16  
17 Two investigators (T.Y. and K.H.) independently reviewed each study to determine its eligibility,  
18  
19 and then extracted and tabulated all of the relevant data. Disagreement was resolved by consensus  
20  
21 between the two investigators.  
22  
23

24  
25 The following information was obtained from each study: first author, year of publication, type of  
26  
27 study, country where the study was conducted, number of subjects (all subjects who participated in  
28  
29 the study), CHD events, method of assessing baldness, follow-up period, mean age, smoking,  
30  
31 covariates used for adjustment during analysis, and severity of baldness.  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### **Statistical analysis**

44 The pooled relative risk (RR) adjusted for possible covariates and its 95% confidence interval  
45  
46 (95%CI) were calculated for the risk of CHD events in each study by the DerSimonian-Laird  
47  
48 random effect model weighted with inverse variance (16). Equivalence of RRs between the cohort  
49  
50 studies and the cross-sectional studies was assessed by the z-statistic test. Cochrane's  $\chi^2$  test and the  
51  
52  $I^2$  test were used to evaluate heterogeneity among studies (17). Possible publication bias was  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 evaluated by creating a funnel plot of the effect size for each study versus the standard error (SE).  
7  
8  
9 Funnel plot asymmetry was assessed by the Begg (18) and Egger tests (19). All statistical analyses  
10  
11  
12 were performed with Stata 12.0 software (StataCorp, College Station, TX). Results are expressed as  
13  
14  
15 the mean with 95%CI, unless otherwise indicated. A *P* value of less than 0.05 was considered  
16  
17  
18 significant. All procedures were performed in accordance with the guideline published by the  
19  
20  
21 Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group (20) and the PRISMA  
22  
23  
24 statement (21)(Supplementary Data 1).  
25  
26  
27  
28

## 29 Results

### 30 31 32 *Literature search*

33  
34  
35 **Figure 1** shows a flow chart of the study selection process. We identified a total of 850 reports by  
36  
37  
38 searching the databases. Among these, 834 reports were excluded after review of the title and  
39  
40  
41 abstract, leaving 16 studies for further evaluation. Ten of these 16 studies were excluded after full  
42  
43  
44 text evaluation, chiefly because of the lack of pertinent data. The remaining 6 studies (8-13) fulfilled  
45  
46  
47 the inclusion criteria were used for the present meta-analysis.  
48  
49  
50  
51  
52

### 53 *Study characteristics*

54  
55  
56 The six studies that were selected included three cohort studies and three case-control studies, and  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 their characteristics are summarized in **Table 1**. There were moderate differences with respect to the  
7  
8  
9 country, number of subjects, and method of assessing baldness. The studies were published between  
10  
11  
12 1993 and 2008. Four studies (9-11,13) were conducted in the USA and the other two (8,12) were  
13  
14  
15 conducted in the European Union. The size of the study populations ranged from 1,437 (11) to  
16  
17  
18 19,112 (10) subjects (mean: 6,165 subjects). In five of the six studies (8,10-13), CHD was defined as  
19  
20  
21 non-fatal myocardial infarction. The mean follow-up period ranged from 11 to 14 years. The method  
22  
23  
24 of assessing baldness varied, with a modified or simplified Hamilton scale being employed in four  
25  
26  
27 studies (8,10,11,13) and a personal scale being used in the other two studies (9,12).

28  
29  
30 Three studies (10,11,13) used a modified Hamilton scale that reduced the 12 categories of the  
31  
32  
33 original scale to the following five categories: no baldness (I, II); frontal baldness alone (IIa, III, IIIa,  
34  
35  
36 IVa); mild vertex baldness (III vertex, IV); moderate vertex baldness (V, Va); and severe vertex  
37  
38  
39 baldness (VI, VII). One study (8) used a simplified Hamilton scale, in which the extent of baldness  
40  
41  
42 was classified as follows: none; frontoparietal region (no bald triangle but >3 cm in front of the ear,  
43  
44  
45 or bald triangle but ≤3 cm in front of the ear); crown-top region (thick hair, partly thin hair, bald spot,  
46  
47  
48 or bald top and front); and combined.

49  
50 Among the two studies that employed personal scales, Ford et al. (1996) classified baldness as  
51  
52  
53 none, minimum, moderate, or severe (9). Minimum baldness corresponded to no obvious baldness  
54  
55  
56 when the participant walked into the examining room, while moderate baldness was observable  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 baldness at the first encounter and severe baldness was obvious at the first encounter. In the other  
7  
8  
9 study, Miric et al. (1998) classified baldness as none, frontal, parietal (vertex), or combined (12).

10  
11  
12 The RR for CHD of the subjects with baldness was adjusted for several coronary risk factors (age,  
13  
14 smoking, diabetes, etc.) in each study, but the number of variables differed significantly among the  
15  
16  
17 studies.  
18

19  
20  
21 The reports on all three cross-sectional studies (11-13) explicitly mentioned the limitations of a  
22  
23 cross-sectional design (i.e., it cannot assess causality), the possible biases of each study, and the  
24  
25 influence of covariates. The reports on all three cohort studies (8-10) mentioned the possibility of  
26  
27  
28 misclassification of the severity of baldness.  
29  
30

31  
32 One study found that baldness was not associated with CHD (13), but the other five studies  
33  
34 concluded that baldness was associated with a significantly increased risk of CHD, although the  
35  
36 strength of the association varied.  
37  
38

39  
40  
41 According to the Newcastle-Ottawa quality assessment scale for observational studies, all of the  
42  
43 studies used in the present meta-analysis achieved at least six out of nine points, indicating that the  
44  
45 overall quality of the studies was good (**Supplementary Data 2**).  
46  
47

#### 48 49 50 51 52 *Association of baldness with CHD*

53  
54  
55 Among the six studies with a total of 36,990 subjects that were selected (8-13), no study showed a  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 significant decrease in the risk of CHD for men with baldness.  
7  
8

9 **Figures 2-4** show the results obtained by combining the RRs for CHD with the random-effect  
10  
11 model.  
12

13  
14 In the three cohort studies (8-10), the adjusted RR of CHD for men of all ages with severe baldness  
15  
16 versus those without baldness was 1.32 (95%CI: 1.08 - 1.63;  $P = 0.008$ ;  $P$  for heterogeneity = 0.26;  $I^2 = 25\%$ ) with non-significant heterogeneity. Analysis restricted to younger subjects (<55 years old  
17  
18  
19  
20  
21  
22  
23 or  $\leq 60$  years old at baseline) revealed a similar association of severe baldness with CHD (RR 1.44  
24  
25  
26 (95%CI: 1.11 - 1.86;  $P = 0.006$ ;  $P$  for heterogeneity = 0.59;  $I^2 = 0\%$ ) with non-significant  
27  
28  
29 heterogeneity (**Figure 2**).  
30

31  
32 In the three case-control studies (11-13), the adjusted RR was 1.70 (95%CI: 1.05 - 2.74;  $P = 0.03$ ;  $P$   
33  
34 for heterogeneity = 0.01;  $I^2 = 78\%$ ) for all subjects, while the RR was 1.84 (95%CI: 1.30 - 2.62;  $P =$   
35  
36  
37 0.001;  $P$  for heterogeneity = 0.17;  $I^2 = 44\%$ ) among the younger subjects (**Figure 3**). The difference  
38  
39 of RR values between the cohort and case-control studies was non-significant (all subjects:  $P = 0.15$ ;  
40  
41  
42 patients  $\leq 60$  years old:  $P = 0.07$ ).  
43  
44  
45  
46  
47  
48

#### 49 **Stratified analysis**

50  
51  
52 In the three studies that assessed the severity of baldness by using the modified Hamilton scale  
53  
54  
55 (10,11,13), two studies (10,11) showed that vertex baldness was associated with CHD and that this  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 association was dependent on the severity of baldness. In subjects with severe vertex baldness, the  
7  
8  
9 RR was 1.48 (95%CI: 1.04 - 2.11;  $P = 0.03$ ;  $P$  for heterogeneity = 0.02;  $I^2 = 75\%$ ), while the RR was  
10  
11  
12 1.36 (95%CI: 1.16 - 1.58;  $P < 0.001$ ;  $P$  for heterogeneity = 0.95;  $I^2 = 0\%$ ) for moderate vertex  
13  
14  
15 baldness and 1.18 (95%CI: 1.04 - 1.35;  $P < 0.001$ ;  $P$  for heterogeneity = 0.35;  $I^2 = 4\%$ ) for mild  
16  
17  
18 vertex baldness. In contrast, there was non-significant association of frontal baldness with CHD and  
19  
20  
21 the RR was only 1.11 (95%CI: 0.92 - 1.32;  $P = 0.28$ ;  $P$  for heterogeneity=0.24;  $I^2 = 30\%$ ) (**Figure**  
22  
23  
24 **4**).

25  
26 Because the method of assessing baldness was not homogenous, we also performed a sensitivity  
27  
28  
29 analysis of the studies that used personal scales to classify baldness into four grades (none, frontal,  
30  
31  
32 crown-top, or combined) (8,12). Similar results were obtained showing that the association with  
33  
34  
35 CHD depended on the severity of baldness, with an RR of 1.69 (95%CI: 1.28 - 2.23;  $P < 0.001$ ;  $P$   
36  
37  
38 for heterogeneity = 0.97;  $I^2 = 0\%$ ) for combined baldness, an RR of 1.52 (95%CI: 0.97- 2.39;  $P =$   
39  
40  
41 0.07;  $P$  for heterogeneity = 0.001;  $I^2 = 91\%$ ) for crown-top baldness, and an RR of 1.22 (95%CI:  
42  
43  
44 0.70 - 2.14;  $P = 0.49$ ;  $P$  for heterogeneity = 0.05;  $I^2 = 73\%$ ) for frontal baldness.  
45  
46  
47  
48

#### 49 ***Publication bias***

50  
51  
52 The funnel plot, Begg's test, and Egger's test were used to evaluate the potential influence of  
53  
54  
55 publication bias on the association between baldness and CHD. The funnel plot did not show an  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 asymmetric pattern, while Egger's test and Begg's test revealed non-significant publication bias (all  
7  
8  
9  $P \geq 0.05$ ).

## 10 11 12 13 14 15 **Discussion**

16  
17  
18 The present meta-analysis of six studies from the USA and Europe demonstrated that vertex  
19  
20 baldness was significantly associated with an increased risk of CHD among subjects of all ages and  
21  
22 also among younger men. Interestingly, frontal baldness was non-significantly associated with CHD.  
23  
24

25  
26 When baldness was classified by the Hamilton-Norwood scale, which is the most commonly used  
27  
28 classification of male pattern baldness worldwide (22), the relationship between CHD and baldness  
29  
30 was shown to be dependent on the severity of baldness.  
31  
32

33  
34  
35 Our meta-analysis of young men alone also showed a significant relationship between androgenetic  
36  
37 alopecia (AGA) and the risk of CHD like that revealed by the meta-analysis of men of all ages (Figs.  
38  
39 2,3). The results were consistent with those of many studies published so far, which have shown that  
40  
41 early onset of AGA is related to a risk of early severe CHD and its risk factors (23-26).  
42  
43  
44

45  
46 These findings support the hypothesis that vertex baldness is a local manifestation of factors  
47  
48 promoting systemic atherosclerosis, such as metabolic syndrome, hypertension, and smoking.  
49  
50

51  
52 Minoxidil (Rogaine/Regaine) is one of the most popular drugs for the treatment of male pattern  
53  
54 baldness. Minoxidil was originally developed as an antihypertensive agent (vasodilator) and it is  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 thought to improve the blood flow and the supply of oxygen and nutrients to the hair follicles by  
7  
8  
9 dilating vessels in the scalp and opening potassium channels. This might lead to the shedding of  
10  
11  
12 hairs in the telogen phase, which are then replaced by thicker hairs in the anagen phase (27).

13  
14 Minoxidil is only indicated for vertex baldness and is ineffective for frontal baldness (28), which  
15  
16  
17 supports our finding that vertex baldness is more closely related to atherosclerosis than frontal  
18  
19  
20 baldness.  
21

### 22 23 24 25 26 *Mechanism of the relation between baldness and CHD* 27

28  
29 The reason for the association between baldness and CHD is unclear. It has been suggested that  
30  
31  
32 classical coronary risk factors (e.g., age, hypertension, dislipidemia, and smoking) might influence  
33  
34  
35 both conditions, so that baldness is a marker of atherosclerosis. In fact, previous studies have  
36  
37  
38 demonstrated a positive association between male pattern baldness and insulin resistance (23),  
39  
40  
41 metabolic syndrome (29), and hypertension (30). It has also been postulated that baldness is linked  
42  
43  
44 to CHD by mechanisms such as hyperinsulinemia, chronic inflammation, and increased peripheral  
45  
46  
47 sensitivity to androgens, and these are briefly discussed below.

48  
49 1) Hyperinsulinemia/insulin resistance is the central factor in metabolic syndrome and it promotes  
50  
51  
52 intolerance of carbohydrates and the development of central (abdominal) obesity. Insulin resistance  
53  
54  
55 has also been shown to cause vasoconstriction and impairs the supply of nutrients to the hair follicles  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 of the scalp, as well as enhancing the influence of dihydro-testosterone (DHT) on follicular  
7  
8  
9 miniaturization (24,31).

10  
11 2) A proinflammatory state could increase the levels of inflammatory cytokines in the arterial walls  
12  
13 (32) and hair follicles (25). High-sensitivity C-reactive protein is a marker of inflammation and is  
14  
15 also a good predictor of future cardiovascular disease (33), so chronic inflammation could be related  
16  
17 to both CHD and baldness.  
18  
19

20  
21 3) Male pattern baldness might be caused by increased peripheral sensitivity to androgens, since bald  
22  
23 men show an increase of androgen receptors in the scalp (34) and have higher serum levels of both  
24  
25 total and free testosterone (35). Free testosterone is converted to DHT by 5 $\alpha$ -reductase, leading to  
26  
27 miniaturization of hair follicles. It has been reported that 5 $\alpha$ -reductase exists in the blood vessels and  
28  
29 the heart, as does the DHT receptor, which is involved in vascular smooth muscle proliferation that  
30  
31 represents a fundamental feature of atherosclerosis along with the deposition of lipids (36).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 ***Strengths and limitations***

44  
45  
46 The strengths of the present meta-analysis were as follows. First, our analysis included several  
47  
48 large cohort and case-control studies, with a total of 36,990 subjects. Second, the cohort studies had  
49  
50 a long follow-up period (11.0-14.0 years). In all of the studies, analyses were adjusted for various  
51  
52 classical coronary risk factors, such as age, smoking, hypertension, dyslipidemia, and body mass  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 index.

7  
8  
9 However, the present meta-analysis also had several limitations. First, we only reviewed  
10  
11 English-language reports for inclusion in this meta-analysis and we might possibly have overlooked  
12  
13 some non-English literature, which could have led to selection bias. However, we also investigated  
14  
15 all of the references in each study as far as possible. Also, our analyses of publication bias did not  
16  
17 suggest that unpublished results had been missed, but these analyses might have been underpowered  
18  
19 due to the small effect sizes. Second, although most factors showed non-significant between-study  
20  
21 heterogeneity, it was significant for some factors, suggesting that differences of epidemiological  
22  
23 characteristics (e.g., the rate of severe baldness or CHD) or different diagnostic criteria (for baldness  
24  
25 and/or CHD) contributed to the heterogeneity to some extent.  
26  
27  
28

29 Unlike the results of the other studies, the effect sizes reported by Lesko et al. (1993) (11) varied  
30  
31 widely and even changed the sign when different patterns of baldness were compared (Fig. 4). This  
32  
33 study had the lowest validity score (6/9 points on the Newcastle-Ottawa scale) among the six studies  
34  
35 included in our meta-analysis (**Supplementary Data 2**). Lesko et al. contacted the coronary care  
36  
37 units of participating hospitals to identify potential subjects with their first myocardial infarction and  
38  
39 to obtain permission to conduct an interview. Thus, details about CHD were not obtained in this  
40  
41 study, which might have led to bias and influenced the effect size.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55 Moreover, as already reported by Rebora (2001)(37), Lotufo et al. (2000)(10) relied on each  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 patient's memory of a condition that had developed up to 40 years before, which might have led to  
7  
8  
9 recall bias. These two studies would have a higher risk of misclassification bias that could lead to  
10  
11  
12 underestimating the strength of the association between baldness and CHD, since it is often  
13  
14  
15 considered shameful to admit to the existence of baldness.

16  
17  
18 The third limitation was incomplete information about the use of medications such as anticoagulants,  
19  
20  
21 anticonvulsants, beta-blockers, antidepressants, and hormone replacement therapy that might have  
22  
23  
24 contributed to baldness (38).

25  
26  
27 Fourth, the methods used to assess baldness varied between studies, which meant that we could not  
28  
29  
30 rule out other local causes of diffuse hair loss (alopecia areata or nonscarring alopecia), as well as  
31  
32  
33 possible systemic causes (e.g., thyroiditis, iron deficiency (39,40), trauma, excessive dieting, or  
34  
35  
36 debilitating diseases).

37  
38  
39 Even with such limitations, the present meta-analysis provided useful evidence regarding the  
40  
41  
42 potential influence of baldness on CHD. Patients and physicians should consider the possibility that  
43  
44  
45 baldness is associated with an increased risk of CHD.

### 46 47 48 49 **Conclusions**

50  
51  
52 In the present meta-analysis, vertex baldness was significantly associated with an increased risk of  
53  
54  
55 CHD among younger men as well as among all subjects, and the association was dependent on the  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 severity of baldness. These findings suggest that vertex baldness is more closely associated with  
7  
8  
9 systemic atherosclerosis than with frontal baldness. Thus, cardiovascular risk factors should be  
10  
11  
12 reviewed carefully in men with vertex baldness, especially younger men, and they probably should  
13  
14  
15 be encouraged to improve their cardiovascular risk profile. However, the usefulness of CHD  
16  
17  
18 screening in asymptomatic populations is yet to be elucidated, so the screening method (e.g.,  
19  
20  
21 exercise ECG, coronary computed tomography, or scintigraphy) employed should be practicable in  
22  
23  
24 terms of its advantages/disadvantages and cost performance, and patients should be evaluated for  
25  
26  
27 eligibility before screening to avoid possible over- medicalization since male pattern baldness affects  
28  
29  
30 30-40% of adult men (5).

31  
32 In addition, the association between baldness and CHD should be investigated in further studies,  
33  
34  
35 including well-designed and controlled cohort studies, in order to confirm whether persons with  
36  
37  
38 male pattern baldness (especially severe vertex baldness) have an increased risk of CHD.  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 ***Contributors***

48  
49 TY, KH, HU and TK conceived the idea of the study and were responsible for the design of the study.

50  
51  
52 TY and KH were responsible for undertaking for the data analysis and produced the tables and  
53  
54  
55 figures. TY and KH provided input into the data analysis. The initial draft of the manuscript was  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 prepared by TY and KH and then circulated repeatedly among all authors for critical revision. TY  
7  
8  
9 was responsible for the acquisition of the data and TY, KH and TK contributed to the interpretation  
10  
11  
12 of the results.  
13

### 14 15 16 17 18 ***Copyright/license for publication*** 19

20  
21 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
22  
23 all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis  
24  
25 to the BMJ Publishing Group Ltd. and its Licensees to permit this article (if accepted) to be  
26  
27 published in BMJ editions and any other BMJ PGL products and sublicenses to exploit all subsidiary  
28  
29 rights, as set out in our license  
30  
31  
32 (http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication).  
33  
34  
35

### 36 37 38 ***Competing Interests*** 39

40  
41 All authors have completed the Unified Competing Interest form at  
42  
43 www.icmje.org/coi\_disclosure.pdf (available on request from the corresponding author) and declare:  
44  
45  
46 no support from any organisation for the submitted work; no financial relationships with any  
47  
48 organisations that might have an interest in the submitted work in the previous three years; no other  
49  
50 relationships or activities that could appear to have influenced the submitted work.  
51  
52  
53

### 54 55 ***Ethical approval*** 56 57 58 59 60

1  
2  
3  
4  
5  
6 Not needed.  
7  
8

9 ***Funding statement***

10  
11 This research received no specific grant from any funding agency in the public, commercial or  
12  
13 not-for-profit sectors.  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 ***Supplementary Data***

24  
25  
26 **Supplementary Data 1. PRISMA Checklist.**  
27  
28

29 **Supplementary Data 2. Newcastle-Ottawa quality assessment scale for observational studies**  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Lopez AD, Mathers CD, Ezzati M, *et al.* Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;367:1747-57.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J* 1986;111:383-90.
3. Young LH, Wackers FJ, Chyun DA, *et al.*; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301:1547-55.
4. McEvoy JW, Blaha MJ, Nasir K, *et al.* Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population. *Arch Intern Med* 2011;171:1260-8.
5. Olsen EA. Androgenetic alopecia. In: Olsen EA ed. *Disorders of Hair Growth: Diagnosis and Treatment*. New York, NY: McGraw-Hill; 1994:257-83.
6. Hamilton JB. Patterned loss of hair in man; types and incidence. *Ann N Y Acad Sci* 1951;53:708-28.
7. Price VH. Treatment of hair loss. *N Engl J Med* 1999;341:964-73.
8. Schnohr P, Lange P, Nyboe J, *et al.* Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. *Am Heart J* 1995;130:1003-10.

- 1  
2  
3  
4  
5  
6 9. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men.  
7  
8  
9 Am J Epidemiol 1996;143:651-7.  
10  
11  
12 10. Lotufo PA, Chae CU, Ajani UA, *et al.* Male pattern baldness and coronary heart disease: the  
13  
14 Physicians' Health Study. Arch Intern Med 2000;160:165-71.  
15  
16  
17 11. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial  
18  
19 infarction in men. JAMA 1993;269:998-1003.  
20  
21  
22 12. Mirić D, Fabijanić D, Giunio L, *et al.* Dermatological indicators of coronary risk: a case-control  
23  
24 study. Int J Cardiol 1998;67:251-5.  
25  
26  
27 13. Shahar E, Heiss G, Rosamond WD, *et al.* Baldness and myocardial infarction in men: the  
28  
29 atherosclerosis risk in communities study. Am J Epidemiol 2008;167:676-83.  
30  
31  
32 14. von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational  
33  
34 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin  
35  
36 Epidemiol 2008;61:344-9.  
37  
38  
39 15. Wells G, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the  
40  
41 quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute.  
42  
43 Available from [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed 4  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*.1986  
7  
8  
9 Sep;7(3):177-88.  
10  
11  
12 17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*  
13  
14  
15 2002;21:1539-58.  
16  
17  
18 18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  
19  
20  
21 *Biometrics*. 1994 Dec;50(4):1088-101.  
22  
23  
24 19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,  
25  
26  
27 graphical test. *BMJ*. 1997 Sep 13;315(7109):629-34  
28  
29  
30 20. Stroup DF, Berlin JA, Morton SC, *et al*. Meta-analysis of observational studies in epidemiology:  
31  
32 a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.  
33  
34  
35 *JAMA* 2000;283:2008-12.  
36  
37  
38 21. Liberati A, Altman DG, Tetzlaff J, *et al*. The PRISMA statement for reporting systematic reviews  
39  
40  
41 and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.  
42  
43  
44 *Ann Intern Med* 2009;151:W65-94.  
45  
46  
47 22. Norwood OT. Male pattern baldness: classification and incidence. *South Med J*  
48  
49  
50 1975;68:1359-65.  
51  
52  
53 23. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic  
54  
55  
56 syndrome in male patients with early-onset androgenetic alopecia. *Eur J Dermatol* 2011;21:79-82.  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 24. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of  
7  
8  
9 insulin resistance. *Lancet* 2000;356:1165-6.  
10  
11  
12 25. Hirso P, Rajala U, Hiltunen L, *et al.* Obesity and low-grade inflammation among young Finnish  
13  
14 men with early-onset alopecia. *Dermatology* 2007;214:125-9.  
15  
16  
17 26. Matilainen VA, Mäkinen PK, Keinänen-Kiukaanniemi SM. Early onset of androgenetic alopecia  
18  
19 associated with early severe coronary heart disease: a population-based, case-control study. *J*  
20  
21 *Cardiovasc Risk*. 2001 Jun;8(3):147-51.  
22  
23  
24 27. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. *Br J Dermatol*  
25  
26  
27 2004;150:186-94.  
28  
29  
30 28. Scow DT, Nolte RS, Shaughnessy AF. Medical treatments for balding in men. *Am Fam*  
31  
32 *Physician* 1999;59:2189-94.  
33  
34  
35 29. Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: a  
36  
37  
38 community-based survey. *Br J Dermatol* 2010;163:371-7.  
39  
40  
41 30. Ahouansou S, Le Toumelin P, Crickx B, *et al.* Association of androgenetic alopecia and  
42  
43  
44 hypertension. *Eur J Dermatol* 2007;17:220-2.  
45  
46  
47 31. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, *et al.* Male androgenetic  
48  
49  
50 alopecia and cardiovascular risk factors: A case-control study. *Actas Dermosifilogr*  
51  
52  
53 2010;101:248-56.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 32. Yudkin JS, Stehouwer CD, Emeis JJ, *et al.* C-reactive protein in healthy subjects: associations  
7  
8  
9 with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines  
10  
11  
12 originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999;19:972-8.  
13  
14  
15 33. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and  
16  
17  
18 prevention. *Circulation* 2003;107:363-9.  
19  
20  
21 34. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher  
22  
23  
24 levels of androgen receptors than those from non-balding scalp. *J Endocrinol* 1998;156:59-65.  
25  
26  
27 35. Demark-Wahnefried W, Lesko SM, Conaway MR, *et al.* Serum androgens: associations with  
28  
29  
30 prostate cancer risk and hair patterning. *J Androl* 1997;18:495-500.  
31  
32  
33 36. Fujimoto R, Morimoto I, Morita E, *et al.* Androgen receptors, 5 $\alpha$ -reductase activity and  
34  
35  
36 androgen-dependent proliferation of vascular smooth muscle cells. *J Steroid Biochem Mol Biol*  
37  
38  
39 1994;50:169-74.  
40  
41  
42 37. Rebora A. Baldness and coronary artery disease: the dermatologic point of view of a  
43  
44  
45 controversial issue. *Arch Dermatol* 2001;137:943-7.  
46  
47  
48 38. Llau ME, Viraben R, Montastruc JL. [Drug-induced alopecia: review of the literature]. *Therapie*  
49  
50  
51 1995;50:145-50.  
52  
53  
54 39. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its  
55  
56  
57 potential relationship to hair loss. *J Am Acad Dermatol* 2006;54:824-44.  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

40. Olsen EA. Iron deficiency and hair loss: the jury is still out. *J Am Acad Dermatol* 2006;54:903-6.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2012-002537 on 3 April 2013. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6 **Figure legends**  
7  
8

9 **Figure 1. Flow diagram of study selection.**

10  
11 **Figure 2. Association of baldness with CHD in the 3 cohort studies.**

12  
13  
14 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
15  
16 disease (CHD). CI=confidence interval; RR=relative risk.  
17  
18

19  
20  
21 **Figure 3. Association of baldness with CHD in the 3 case-control studies.**

22  
23  
24 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
25  
26 disease (CHD). CI=confidence interval; RR=relative risk.  
27  
28

29  
30 **Figure 4. Association of baldness with CHD in studies using the modified Hamilton scale.**

31  
32 The forest plot shows the association between male pattern baldness and the risk of coronary heart  
33  
34 disease (CHD). CI=confidence interval; RR=relative risk  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

---

First author,	Type of	Country	Subjects	CHD (events)	Assessment of baldness	Follow-up	Covariates used for adjustment
---------------	---------	---------	----------	--------------	------------------------	-----------	--------------------------------

---

For peer review only

Table 1. Summary of studies evaluating the association between baldness and coronary heart disease

year of publication	study					(years)	
Schnohr, 1995 (8)	Cohort	Denmark	5837	Myocardial infarction (750)	Simplified Hamilton (None, Frontoparietal, Crown-top, Combined)	12.0	Age, smoking, systolic blood pressure, cholesterol, triglycerides, physical activity, BMI, family history of MI, marital status, education, economic status, diabetes, and alcohol consumption
Ford, 1996 (9)	Cohort	USA	3994	Ischemic heart disease (965)	Personal scale (None, Minimum, Moderate, Severe)	14.0	Age, age squared, race, education, systolic blood pressure, antihypertensive medication, cholesterol, smoking, BMI, and diabetes mellitus
Lotufo, 2000 (10)	Cohort	USA	19112	Nonfatal MI, angina, coronary revascularization (1446)	Modified Hamilton (None, Frontal, Mild vertex, Moderate vertex, Severe vertex)	11.0	Age, aspirin assignment, beta carotene assignment, BMI, height (cm), hypertension, hypercholesterolemia, diabetes, parental history of MI, physical activity, smoking, and alcohol use.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

Lesko,	Case-	USA	1437	Non-fatal	Modified Hamilton (None,	-	Age, race, religion, years of education, BMI, use of
1993 (11)	control			Myocardial	Frontal only, Mild vertex,		alcohol and cigarettes, family history of myocardial
				infarction (665)	Moderate vertex, Severe vertex)		infarction, personal history of angina, hypertension,
							diabetes, hypercholesterolemia, gout, exercise,
							personality, and number of doctor visits in the past year.
Miric,	Case-	Croatia	1554	Non-fatal	Personal score ( None, Any,	-	Age, family history of MI, hypertension,
1998 (12)	control			Myocardial	Frontal, Parietal, Fronto-parietal)		hypercholesterolemia, BMI, diabetes, and smoking.
				infarction (842)			
Shahar,	Case-	USA	5056	Non-fatal	Modified Hamilton ( None,	-	Age, smoking, BMI, race-center, cholesterol-lowering
2008 (13)	control			Myocardial	Frontal, Mild vertex, Moderate		medication, antihypertensive medication, HDL,
				infarction (767)	vertex, Severe vertex)		diabetes, educational level, and family history of MI.

CHD, coronary heart disease; BMI, body mass index; MI, myocardial infarction; AGA, androgenic alopecia; HDL, high density lipoprotein;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

1  
2  
3  
4  
5  
6 **Male Pattern Baldness and Its Association with Coronary Heart Disease: A Meta-Analysis**  
7

8 Tomohide Yamada, MD

9  
10  
11 Kazuo Hara, MD, PhD\*

12  
13 Hitomi Umematsu, MD

14  
15  
16  
17 Takashi Kadowaki, MD, PhD

18  
19  
20 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine

21  
22 University of Tokyo, Japan

23  
24  
25  
26 \* Corresponding author

27  
28  
29 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan

30  
31  
32 Tel.: +81-3-5800-8818; Fax: +81-3-5689-7209

33  
34  
35 E-mail address: [haratky@gmail.com](mailto:haratky@gmail.com)

36  
37  
38  
39  
40 **Brief title:** Male pattern baldness and CHD

41  
42  
43  
44  
45  
46 **Word count:** 3691 words

**Abstract****Objective:**

To confirm the association between male pattern baldness and coronary heart disease (CHD).

**Design:**

Meta-analysis of observational studies.

**Data sources:**

Medline and the Cochrane Library were searched for articles published up to November 2012 using keywords that included both 'baldness' and 'coronary heart disease' and the reference lists of those studies identified were also searched.

**Study selection:**

Observational studies were identified that reported risk estimates for CHD related to baldness. Two observers independently assessed eligibility, extracted data, and assessed the possibility of bias.

**Data synthesis:**

The adjusted relative risk (RR) and 95% confidence interval (95%CI) were estimated using the DerSimonian-Laird random-effect model.

**Results:**

Included 850 possible studies, three cohort studies and three case-control studies were selected (36,990 subjects).



1  
2  
3  
4  
5  
6 In the cohort studies, the adjusted RR of men with severe baldness for CHD was 1.32 (95%CI: 1.08 -  
7  
8  
9 1.63,  $P = 0.008$ ,  $I^2 = 25\%$ ) versus those without baldness. Analysis of younger men (<55 or ≤60  
10  
11  
12 years) showed a similar association of CHD with severe baldness (RR: 1.44, 95%CI: 1.11 - 1.86,  $P =$   
13  
14 0.006,  $I^2 = 0\%$ ).

15  
16  
17 In 3 studies employing the modified Hamilton scale, vertex baldness was associated with CHD and  
18  
19  
20 the relation depended on the severity of baldness (severe vertex: RR 1.48 (1.04 - 2.11,  $P = 0.03$ );  
21  
22 moderate vertex: RR 1.36 (1.16 - 1.58,  $P < 0.001$ ); mild vertex: RR 1.18 (1.04 - 1.35,  $P < 0.001$ ).  
23  
24  
25 However, frontal baldness was not associated with CHD (RR 1.11 (0.92 - 1.32,  $P = 0.28$ )).  
26  
27

#### 28 29 **Conclusion:**

30  
31  
32 Vertex baldness, but not frontal baldness, is associated with an increased risk of CHD. The  
33  
34  
35 association with CHD depends on the severity of vertex baldness and also exists among younger  
36  
37  
38 men. Thus, vertex baldness might be more closely related to atherosclerosis than frontal baldness,  
39  
40  
41 but the association between male pattern baldness and CHD deserves further investigation.  
42  
43  
44  
45

46  
47 **Key words:** male pattern baldness, androgenetic alopecia, coronary heart disease, cardiovascular  
48  
49  
50 disease, relative risk, meta-analysis  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article summary

### Article focus:

• The present meta-analysis aimed to confirm the association of male pattern baldness (androgenetic alopecia) with an increased risk of coronary heart disease (CHD).

### Key messages:

• Meta-analysis of 6 observational studies with a total of 36,690 subjects showed that vertex baldness is associated with an increased risk of CHD and that the relationship depends upon the severity of baldness, while frontal baldness is not.

• Thus, vertex baldness might be a marker of CHD and is more closely associated with systemic atherosclerosis than frontal baldness.

• This potential relationship should be investigated in further studies, including well-designed prospective studies.

### Strengths and limitations of this study:

• This was the first meta-analysis of the association between baldness and CHD; it showed that the relationship depends on the severity of baldness.

• The cohort studies had a long follow-up period of 11.0 - 14.0 years.

• A weakness might be the small number of studies analyzed.

## Introduction

Coronary heart disease (CHD) is a major cause of death and disability worldwide (1). Advanced obstructive CHD can exist in patients with minimal or no symptoms and can progress rapidly (2), so early detection is extremely important. Many clinicians carry out screening for asymptomatic CHD and participants in wellbeing programs often also request such screening, but the usefulness of CHD screening has yet to be confirmed. Young et al. (2009) reported that the incidence of CHD was not significantly reduced in asymptomatic diabetic patients when screening was conducted by myocardial scintigraphy (3), and McEvoy et al. (2011) also reported that coronary computed tomography screening of asymptomatic patients without a history of coronary artery disease fails to prevent major cardiovascular events (4).

Male pattern baldness, also called androgenetic alopecia (AGA), is the most common cause of hair loss. It affects approximately 30 to 40% of adult men (5) and it is seen in 80% of men by the age of 80 years (6). AGA is considered to be a heritable, androgen-dependent condition that is characterized by varying degrees of thinning/hair loss primarily at the vertex and the frontal areas (temples) of the scalp. In men with AGA, the thin residual hairs tend to be of various lengths and diameters since each follicle is in a different phase of the hair cycle, so the presence of variations in hair length and texture is a classic feature of this thinning condition (7).

Several recent studies have shown that baldness is associated with the risk of CHD (8-12). These

1  
2  
3  
4  
5  
6 studies have generally found a positive association between baldness and CHD, although the  
7  
8 strength of the association has varied (8-13).

9  
10  
11 Clarifying the relationship between baldness and CHD could lead to more effective approaches to  
12  
13 the early detection of heart disease, since it might permit the reliable identification of persons with  
14  
15 an increased risk of suffering from a cardiac event thereby allowing the delivery of appropriate  
16  
17 therapy (e.g., antihypertensive or lipid-lowering therapy) to improve the prognosis of such high-risk  
18  
19 persons. Accordingly, we performed a meta-analysis to further assess the influence of male pattern  
20  
21 baldness (AGA) on CHD.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 **Methods**

### 33 *Search strategy*

34  
35  
36  
37  
38 The Medline and Cochrane Library electronic databases were searched from January 1, 1950 until  
39  
40 November 27, 2012 using the medical subject headings “Baldness” (“baldness” or “hair loss” or  
41  
42 “alopecia”) and “Coronary heart disease” (“coronary heart disease” or “cardiovascular disease” or  
43  
44 “coronary artery disease”) to identify observational studies that estimated the association between  
45  
46 baldness and CHD. The reference lists of all studies identified were also reviewed.  
47  
48  
49  
50  
51

### 52 *Study selection*

1  
2  
3  
4  
5  
6 We performed initial screening based on the study titles or abstracts, while the second screening  
7  
8  
9 involved a full-text review. Cohort studies, case-control studies, and cross-sectional studies that  
10  
11  
12 assessed the association between male pattern baldness and CHD were eligible for inclusion if the  
13  
14  
15 following criteria were met: 1) the full text of the report was published in English, 2) the relative risk  
16  
17  
18 (risk ratio, hazard ratio, or odds ratio) was reported with adjustment for possible covariates (e.g. age,  
19  
20  
21 smoking, family history of baldness, or family history of CHD), 3) the presence and severity of male  
22  
23  
24 pattern baldness was reported, and 4) CHD events were reported.  
25  
26  
27  
28

### 29 *Definitions of baldness and CHD*

30  
31  
32 Baldness was defined according to the description in the history and/or on the basis of terms such  
33  
34  
35 as AGA and male pattern hair loss. We excluded studies that analyzed men with other types of  
36  
37  
38 baldness (e.g., alopecia areata or scarring alopecia). CHD was defined as including all of the  
39  
40  
41 following: coronary artery disease, myocardial infarction, angina pectoris, cardiomyopathy, and  
42  
43  
44 other types of ischemic heart disease.  
45  
46  
47  
48

### 49 *Assessment of validity*

50  
51  
52 To ascertain the validity of the eligible studies, the quality of each report was appraised with  
53  
54  
55 reference to the STROBE statement (14). Moreover, the Newcastle-Ottawa Scale for assessing  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 quality of non-randomized studies in meta-analyses was used to quantify the validity of each study  
7  
8  
9 (15).

### 10 11 12 13 14 15 **Data extraction**

16  
17 Two investigators (T.Y. and K.H.) independently reviewed each study to determine its eligibility,  
18  
19 and then extracted and tabulated all of the relevant data. Disagreement was resolved by consensus  
20  
21 between the two investigators.  
22  
23

24  
25 The following information was obtained from each study: first author, year of publication, type of  
26  
27 study, country where the study was conducted, number of subjects (all subjects who participated in  
28  
29 the study), CHD events, method of assessing baldness, follow-up period, mean age, smoking,  
30  
31 covariates used for adjustment during analysis, and severity of baldness.  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Statistical analysis**

44 The pooled relative risk (RR) adjusted for possible covariates and its 95% confidence interval  
45  
46 (95%CI) were calculated for the risk of CHD events in each study by the DerSimonian-Laird  
47  
48 random effect model weighted with inverse variance (16). Equivalence of RRs between the cohort  
49  
50 studies and the cross-sectional studies was assessed by the z-statistic test. Cochrane's  $\chi^2$  test and the  
51  
52  $I^2$  test were used to evaluate heterogeneity among studies (17). Possible publication bias was  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 evaluated by creating a funnel plot of the effect size for each study versus the standard error (SE).  
7  
8  
9 Funnel plot asymmetry was assessed by the Begg (18) and Egger tests (19). All statistical analyses  
10  
11  
12 were performed with Stata 12.0 software (StataCorp, College Station, TX). Results are expressed as  
13  
14  
15 the mean with 95%CI, unless otherwise indicated. A P value of less than 0.05 was considered  
16  
17  
18 significant. All procedures were performed in accordance with the guideline published by the  
19  
20  
21 Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group (20) and the PRISMA  
22  
23  
24 statement (21)(Supplementary Data 1).  
25  
26  
27  
28

## 29 Results

### 30 Literature search

31  
32  
33  
34  
35 **Figure 1** shows a flow chart of the study selection process. We identified a total of 850 reports by  
36  
37  
38 searching the databases. Among these, 834 reports were excluded after review of the title and  
39  
40  
41 abstract, leaving 16 studies for further evaluation. Ten of these 16 studies were excluded after full  
42  
43  
44 text evaluation, chiefly because of the lack of pertinent data. The remaining 6 studies (8-13) fulfilled  
45  
46  
47 the inclusion criteria were used for the present meta-analysis.  
48  
49  
50  
51  
52

### 53 Study characteristics

54  
55 The six studies that were selected included three cohort studies and three case-control studies, and  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 their characteristics are summarized in **Table 1**. There were moderate differences with respect to the  
7  
8  
9 country, number of subjects, and method of assessing baldness. The studies were published between  
10  
11  
12 1993 and 2008. Four studies (9-11,13) were conducted in the USA and the other two (8,12) were  
13  
14  
15 conducted in the European Union. The size of the study populations ranged from 1,437 (11) to  
16  
17  
18 19,112 (10) subjects (mean: 6,165 subjects). In five of the six studies (8,10-13), CHD was defined as  
19  
20  
21 non-fatal myocardial infarction. The mean follow-up period ranged from 11 to 14 years. The method  
22  
23  
24 of assessing baldness varied, with a modified or simplified Hamilton scale being employed in four  
25  
26  
27 studies (8,10,11,13) and a personal scale being used in the other two studies (9,12).

28  
29  
30 Three studies (10,11,13) used a modified Hamilton scale that reduced the 12 categories of the  
31  
32  
33 original scale to the following five categories: no baldness (I, II); frontal baldness alone (IIa, III, IIIa,  
34  
35  
36 IVa); mild vertex baldness (III vertex, IV); moderate vertex baldness (V, Va); and severe vertex  
37  
38  
39 baldness (VI, VII). One study (8) used a simplified Hamilton scale, in which the extent of baldness  
40  
41  
42 was classified as follows: none; frontoparietal region (no bald triangle but >3 cm in front of the ear,  
43  
44  
45 or bald triangle but ≤3 cm in front of the ear); crown-top region (thick hair, partly thin hair, bald spot,  
46  
47  
48 or bald top and front); and combined.

49  
50  
51 Among the two studies that employed personal scales, Ford et al. (1996) classified baldness as  
52  
53  
54 none, minimum, moderate, or severe (9). Minimum baldness corresponded to no obvious baldness  
55  
56  
57 when the participant walked into the examining room, while moderate baldness was observable  
58  
59  
60



1  
2  
3  
4  
5  
6 baldness at the first encounter and severe baldness was obvious at the first encounter. In the other  
7  
8  
9 study, Miric et al. (1998) classified baldness as none, frontal, parietal (vertex), or combined (12).

10  
11  
12 The RR for CHD of the subjects with baldness was adjusted for several coronary risk factors (age,  
13  
14 smoking, diabetes, etc.) in each study, but the number of variables differed significantly among the  
15  
16 studies.  
17  
18

19  
20  
21 The reports on all three cross-sectional studies (11-13) explicitly mentioned the limitations of a  
22  
23 cross-sectional design (i.e., it cannot assess causality), the possible biases of each study, and the  
24  
25 influence of covariates. The reports on all three cohort studies (8-10) mentioned the possibility of  
26  
27 misclassification of the severity of baldness.  
28  
29

30  
31  
32 One study found that baldness was not associated with CHD (13), but the other five studies  
33  
34 concluded that baldness was associated with a significantly increased risk of CHD, although the  
35  
36 strength of the association varied.  
37  
38

39  
40  
41 According to the Newcastle-Ottawa quality assessment scale for observational studies, all of the  
42  
43 studies used in the present meta-analysis achieved at least six out of nine points, indicating that the  
44  
45 overall quality of the studies was good (**Supplementary Data 2**).  
46  
47

#### 48 49 50 51 52 *Association of baldness with CHD*

53  
54  
55 Among the six studies with a total of 36,990 subjects that were selected (8-13), no study showed a  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 significant decrease in the risk of CHD for men with baldness.  
7

8  
9 **Figures 2-4** show the results obtained by combining the RRs for CHD with the random-effect  
10  
11 model.  
12

13  
14 In the three cohort studies (8-10), the adjusted RR of CHD for men of all ages with severe baldness  
15 versus those without baldness was 1.32 (95%CI: 1.08 - 1.63;  $P = 0.008$ ;  $P$  for heterogeneity = 0.26;  $I$   
16  $^2 = 25\%$ ) with non-significant heterogeneity. Analysis restricted to younger subjects (<55 years old  
17 or  $\leq 60$  years old at baseline) revealed a similar association of severe baldness with CHD (RR 1.44  
18 (95%CI: 1.11 - 1.86;  $P = 0.006$ ;  $P$  for heterogeneity = 0.59;  $I^2 = 0\%$ )) with non-significant  
19 heterogeneity (Figure 2).  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 In the three case-control studies (11-13), the adjusted RR was 1.70 (95%CI: 1.05 - 2.74;  $P = 0.03$ ;  $P$   
33 for heterogeneity = 0.01;  $I^2 = 78\%$ ) for all subjects, while the RR was 1.84 (95%CI: 1.30 - 2.62;  $P =$   
34 0.001;  $P$  for heterogeneity = 0.17;  $I^2 = 44\%$ ) among the younger subjects (Figure 3). The difference  
35 of RR values between the cohort and case-control studies was non-significant (all subjects:  $P = 0.15$ ;  
36 patients  $\leq 60$  years old:  $P = 0.07$ ).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

#### 49 **Stratified analysis**

50  
51 In the three studies that assessed the severity of baldness by using the modified Hamilton scale  
52 (10,11,13), two studies (10,11) showed that vertex baldness was associated with CHD and that this  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 association was dependent on the severity of baldness. In subjects with severe vertex baldness, the  
7  
8  
9 RR was 1.48 (95%CI: 1.04 - 2.11;  $P = 0.03$ ;  $P$  for heterogeneity = 0.02;  $I^2 = 75\%$ ), while the RR was  
10  
11  
12 1.36 (95%CI: 1.16 - 1.58;  $P < 0.001$ ;  $P$  for heterogeneity = 0.95;  $I^2 = 0\%$ ) for moderate vertex  
13  
14  
15 baldness and 1.18 (95%CI: 1.04 - 1.35;  $P < 0.001$ ;  $P$  for heterogeneity = 0.35;  $I^2 = 4\%$ ) for mild  
16  
17  
18 vertex baldness. In contrast, there was non-significant association of frontal baldness with CHD and  
19  
20  
21 the RR was only 1.11 (95%CI: 0.92 - 1.32;  $P = 0.28$ ;  $P$  for heterogeneity=0.24;  $I^2 = 30\%$ ) (**Figure**  
22  
23  
24 **4**).

25  
26 Because the method of assessing baldness was not homogenous, we also performed a sensitivity  
27  
28  
29 analysis of the studies that used personal scales to classify baldness into four grades (none, frontal,  
30  
31  
32 crown-top, or combined) (8,12). Similar results were obtained showing that the association with  
33  
34  
35 CHD depended on the severity of baldness, with an RR of 1.69 (95%CI: 1.28 - 2.23;  $P < 0.001$ ;  $P$   
36  
37  
38 for heterogeneity = 0.97;  $I^2 = 0\%$ ) for combined baldness, an RR of 1.52 (95%CI: 0.97- 2.39;  $P =$   
39  
40  
41 0.07;  $P$  for heterogeneity = 0.001;  $I^2 = 91\%$ ) for crown-top baldness, and an RR of 1.22 (95%CI:  
42  
43  
44 0.70 - 2.14;  $P = 0.49$ ;  $P$  for heterogeneity = 0.05;  $I^2 = 73\%$ ) for frontal baldness.  
45  
46  
47  
48

#### 49 ***Publication bias***

50  
51  
52 The funnel plot, Begg's test, and Egger's test were used to evaluate the potential influence of  
53  
54  
55 publication bias on the association between baldness and CHD. The funnel plot did not show an  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 asymmetric pattern, while Egger's test and Begg's test revealed non-significant publication bias (all  
7  
8  
9  $P \geq 0.05$ ).

## 10 11 12 13 14 15 **Discussion**

16  
17 The present meta-analysis of six studies from the USA and Europe demonstrated that vertex  
18 baldness was significantly associated with an increased risk of CHD among subjects of all ages and  
19  
20 baldness was significantly associated with an increased risk of CHD among subjects of all ages and  
21  
22 also among younger men. Interestingly, frontal baldness was non-significantly associated with CHD.  
23  
24

25  
26 When baldness was classified by the Hamilton-Norwood scale, which is the most commonly used  
27  
28 classification of male pattern baldness worldwide (22), the relationship between CHD and baldness  
29  
30 was shown to be dependent on the severity of baldness.  
31  
32

33  
34 Our meta-analysis of young men alone also showed a significant relationship between androgenetic  
35  
36 alopecia (AGA) and the risk of CHD like that revealed by the meta-analysis of men of all ages (Figs.  
37  
38 2,3). The results were consistent with those of many studies published so far, which have shown that  
39  
40 early onset of AGA is related to a risk of early severe CHD and its risk factors (23-26).  
41  
42  
43  
44

45  
46 These findings support the hypothesis that vertex baldness is a local manifestation of factors  
47  
48 promoting systemic atherosclerosis, such as metabolic syndrome, hypertension, and smoking.  
49  
50

51  
52 Minoxidil (Rogaine/Regaine) is one of the most popular drugs for the treatment of male pattern  
53  
54 baldness. Minoxidil was originally developed as an antihypertensive agent (vasodilator) and it is  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 thought to improve the blood flow and the supply of oxygen and nutrients to the hair follicles by  
7  
8  
9 dilating vessels in the scalp and opening potassium channels. This might lead to the shedding of  
10  
11  
12 hairs in the telogen phase, which are then replaced by thicker hairs in the anagen phase (27).

13  
14 Minoxidil is only indicated for vertex baldness and is ineffective for frontal baldness (28), which  
15  
16  
17 supports our finding that vertex baldness is more closely related to atherosclerosis than frontal  
18  
19  
20 baldness.  
21

### 22 23 24 25 26 *Mechanism of the relation between baldness and CHD* 27

28  
29 The reason for the association between baldness and CHD is unclear. It has been suggested that  
30  
31  
32 classical coronary risk factors (e.g., age, hypertension, dislipidemia, and smoking) might influence  
33  
34  
35 both conditions, so that baldness is a marker of atherosclerosis. In fact, previous studies have  
36  
37  
38 demonstrated a positive association between male pattern baldness and insulin resistance (23),  
39  
40  
41 metabolic syndrome (29), and hypertension (30). It has also been postulated that baldness is linked  
42  
43  
44 to CHD by mechanisms such as hyperinsulinemia, chronic inflammation, and increased peripheral  
45  
46  
47 sensitivity to androgens, and these are briefly discussed below.

48  
49 1) Hyperinsulinemia/insulin resistance is the central factor in metabolic syndrome and it promotes  
50  
51  
52 intolerance of carbohydrates and the development of central (abdominal) obesity. Insulin resistance  
53  
54  
55 has also been shown to cause vasoconstriction and impairs the supply of nutrients to the hair follicles  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 of the scalp, as well as enhancing the influence of dihydro-testosterone (DHT) on follicular  
7  
8  
9 miniaturization (24,31).

10  
11 2) A proinflammatory state could increase the levels of inflammatory cytokines in the arterial walls  
12  
13 (32) and hair follicles (25). High-sensitivity C-reactive protein is a marker of inflammation and is  
14  
15 also a good predictor of future cardiovascular disease (33), so chronic inflammation could be related  
16  
17 to both CHD and baldness.  
18  
19

20  
21 3) Male pattern baldness might be caused by increased peripheral sensitivity to androgens, since bald  
22  
23 men show an increase of androgen receptors in the scalp (34) and have higher serum levels of both  
24  
25 total and free testosterone (35). Free testosterone is converted to DHT by 5 $\alpha$ -reductase, leading to  
26  
27 miniaturization of hair follicles. It has been reported that 5 $\alpha$ -reductase exists in the blood vessels and  
28  
29 the heart, as does the DHT receptor, which is involved in vascular smooth muscle proliferation that  
30  
31 represents a fundamental feature of atherosclerosis along with the deposition of lipids (36).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 ***Strengths and limitations***

44  
45  
46 The strengths of the present meta-analysis were as follows. First, our analysis included several  
47  
48 large cohort and case-control studies, with a total of 36,990 subjects. Second, the cohort studies had  
49  
50 a long follow-up period (11.0-14.0 years). In all of the studies, analyses were adjusted for various  
51  
52 classical coronary risk factors, such as age, smoking, hypertension, dyslipidemia, and body mass  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 index.

7  
8  
9 However, the present meta-analysis also had several limitations. First, we only reviewed  
10 English-language reports for inclusion in this meta-analysis and we might possibly have overlooked  
11 some non-English literature, which could have led to selection bias. However, we also investigated  
12 all of the references in each study as far as possible. Also, our analyses of publication bias did not  
13 suggest that unpublished results had been missed, but these analyses might have been underpowered  
14 due to the small effect sizes. Second, although most factors showed non-significant between-study  
15 heterogeneity, it was significant for some factors, suggesting that differences of epidemiological  
16 characteristics (e.g., the rate of severe baldness or CHD) or different diagnostic criteria (for baldness  
17 and/or CHD) contributed to the heterogeneity to some extent.

18  
19 Unlike the results of the other studies, the effect sizes reported by Lesko et al. (1993) (11) varied  
20 widely and even changed the sign when different patterns of baldness were compared (Fig. 4). This  
21 study had the lowest validity score (6/9 points on the Newcastle-Ottawa scale) among the six studies  
22 included in our meta-analysis (**Supplementary Data 2**). Lesko et al. contacted the coronary care  
23 units of participating hospitals to identify potential subjects with their first myocardial infarction and  
24 to obtain permission to conduct an interview. Thus, details about CHD were not obtained in this  
25 study, which might have led to bias and influenced the effect size.

26  
27 Moreover, as already reported by Rebora (2001)(37), Lotufo et al. (2000)(10) relied on each  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 patient's memory of a condition that had developed up to 40 years before, which might have led to  
7  
8  
9 recall bias. These two studies would have a higher risk of misclassification bias that could lead to  
10  
11  
12 underestimating the strength of the association between baldness and CHD, since it is often  
13  
14  
15 considered shameful to admit to the existence of baldness.

16  
17  
18 The third limitation was incomplete information about the use of medications such as anticoagulants,  
19  
20  
21 anticonvulsants, beta-blockers, antidepressants, and hormone replacement therapy that might have  
22  
23  
24 contributed to baldness (38).

25  
26  
27 Fourth, the methods used to assess baldness varied between studies, which meant that we could not  
28  
29  
30 rule out other local causes of diffuse hair loss (alopecia areata or nonscarring alopecia), as well as  
31  
32  
33 possible systemic causes (e.g., thyroiditis, iron deficiency (39,40), trauma, excessive dieting, or  
34  
35  
36 debilitating diseases).

37  
38  
39 Even with such limitations, the present meta-analysis provided useful evidence regarding the  
40  
41  
42 potential influence of baldness on CHD. Patients and physicians should consider the possibility that  
43  
44  
45 baldness is associated with an increased risk of CHD.

### 46 47 48 49 **Conclusions**

50  
51  
52 In the present meta-analysis, vertex baldness was significantly associated with an increased risk of  
53  
54  
55 CHD among younger men as well as among all subjects, and the association was dependent on the  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 severity of baldness. These findings suggest that vertex baldness is more closely associated with  
7  
8  
9 systemic atherosclerosis than with frontal baldness. Thus, cardiovascular risk factors should be  
10  
11  
12 reviewed carefully in men with vertex baldness, especially younger men, and they probably should  
13  
14  
15 be encouraged to improve their cardiovascular risk profile. However, the usefulness of CHD  
16  
17  
18 screening in asymptomatic populations is yet to be elucidated, so the screening method (e.g.,  
19  
20  
21 exercise ECG, coronary computed tomography, or scintigraphy) employed should be practicable in  
22  
23  
24 terms of its advantages/disadvantages and cost performance, and patients should be evaluated for  
25  
26  
27 eligibility before screening to avoid possible over- medicalization since male pattern baldness affects  
28  
29  
30 30-40% of adult men (5).

31  
32 In addition, the association between baldness and CHD should be investigated in further studies,  
33  
34  
35 including well-designed and controlled cohort studies, in order to confirm whether persons with  
36  
37  
38 male pattern baldness (especially severe vertex baldness) have an increased risk of CHD.  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 ***Contributors***

48  
49 TY, KH, HU and TK conceived the idea of the study and were responsible for the design of the study.  
50  
51

52  
53 TY and KH were responsible for undertaking for the data analysis and produced the tables and  
54  
55  
56 figures. TY and KH provided input into the data analysis. The initial draft of the manuscript was  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 prepared by TY and KH and then circulated repeatedly among all authors for critical revision. TY  
7  
8  
9 was responsible for the acquisition of the data and TY, KH and TK contributed to the interpretation  
10  
11  
12 of the results.  
13

### 14 15 16 17 18 ***Copyright/license for publication*** 19

20 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
21  
22  
23 all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis  
24  
25  
26 to the BMJ Publishing Group Ltd. and its Licensees to permit this article (if accepted) to be  
27  
28  
29 published in BMJ editions and any other BMJ PGL products and sublicenses to exploit all subsidiary  
30  
31  
32 rights, as set out in our license  
33  
34  
35 (<http://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publication>).  
36  
37

### 38 ***Competing Interests*** 39

40 All authors have completed the Unified Competing Interest form at  
41  
42  
43 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare:  
44  
45  
46 no support from any organisation for the submitted work; no financial relationships with any  
47  
48  
49 organisations that might have an interest in the submitted work in the previous three years; no other  
50  
51  
52 relationships or activities that could appear to have influenced the submitted work.  
53  
54

### 55 ***Ethical approval*** 56 57 58 59 60

1  
2  
3  
4  
5  
6 Not needed.  
7  
8

9 ***Funding statement***

10  
11 This research received no specific grant from any funding agency in the public, commercial or  
12  
13 not-for-profit sectors.  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 ***Supplementary Data***

24  
25  
26 **Supplementary Data 1. PRISMA Checklist.**  
27

28  
29 **Supplementary Data 2. Newcastle-Ottawa quality assessment scale for observational studies**  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Lopez AD, Mathers CD, Ezzati M, *et al.* Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;367:1747-57.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. *Am Heart J* 1986;111:383-90.
3. Young LH, Wackers FJ, Chyun DA, *et al.*; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301:1547-55.
4. McEvoy JW, Blaha MJ, Nasir K, *et al.* Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population. *Arch Intern Med* 2011;171:1260-8.
5. Olsen EA. Androgenetic alopecia. In: Olsen EA ed. *Disorders of Hair Growth: Diagnosis and Treatment*. New York, NY: McGraw-Hill; 1994:257-83.
6. Hamilton JB. Patterned loss of hair in man; types and incidence. *Ann N Y Acad Sci* 1951;53:708-28.
7. Price VH. Treatment of hair loss. *N Engl J Med* 1999;341:964-73.
8. Schnohr P, Lange P, Nyboe J, *et al.* Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. *Am Heart J* 1995;130:1003-10.

- 1  
2  
3  
4  
5  
6 9. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men.  
7  
8  
9 Am J Epidemiol 1996;143:651-7.  
10  
11  
12 10. Lotufo PA, Chae CU, Ajani UA, *et al.* Male pattern baldness and coronary heart disease: the  
13  
14 Physicians' Health Study. Arch Intern Med 2000;160:165-71.  
15  
16  
17 11. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial  
18  
19 infarction in men. JAMA 1993;269:998-1003.  
20  
21  
22 12. Mirić D, Fabijanić D, Giunio L, *et al.* Dermatological indicators of coronary risk: a case-control  
23  
24 study. Int J Cardiol 1998;67:251-5.  
25  
26  
27 13. Shahar E, Heiss G, Rosamond WD, *et al.* Baldness and myocardial infarction in men: the  
28  
29 atherosclerosis risk in communities study. Am J Epidemiol 2008;167:676-83.  
30  
31  
32 14. von Elm E, Altman DG, Egger M, *et al.* The Strengthening the Reporting of Observational  
33  
34 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin  
35  
36 Epidemiol 2008;61:344-9.  
37  
38  
39 15. Wells G, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the  
40  
41 quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute.  
42  
43 Available from [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed 4  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986  
7  
8  
9 Sep;7(3):177-88.  
10  
11 17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*  
12  
13 2002;21:1539-58.  
14  
15  
16  
17 18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  
18  
19 *Biometrics*. 1994 Dec;50(4):1088-101.  
20  
21  
22 19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,  
23  
24 graphical test. *BMJ*. 1997 Sep 13;315(7109):629-34  
25  
26  
27  
28 20. Stroup DF, Berlin JA, Morton SC, *et al*. Meta-analysis of observational studies in epidemiology:  
29  
30 a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.  
31  
32 *JAMA* 2000;283:2008-12.  
33  
34  
35  
36 21. Liberati A, Altman DG, Tetzlaff J, *et al*. The PRISMA statement for reporting systematic reviews  
37  
38 and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.  
39  
40  
41 *Ann Intern Med* 2009;151:W65-94.  
42  
43  
44  
45 22. Norwood OT. Male pattern baldness: classification and incidence. *South Med J*  
46  
47  
48 1975;68:1359-65.  
49  
50  
51 23. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic  
52  
53 syndrome in male patients with early-onset androgenetic alopecia. *Eur J Dermatol* 2011;21:79-82.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6 24. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of  
7  
8  
9 insulin resistance. *Lancet* 2000;356:1165-6.  
10  
11  
12 25. Hirso P, Rajala U, Hiltunen L, *et al.* Obesity and low-grade inflammation among young Finnish  
13  
14  
15 men with early-onset alopecia. *Dermatology* 2007;214:125-9.  
16  
17  
18 26. Matilainen VA, Mäkinen PK, Keinänen-Kiukaanniemi SM. Early onset of androgenetic alopecia  
19  
20  
21 associated with early severe coronary heart disease: a population-based, case-control study. *J*  
22  
23  
24 *Cardiovasc Risk*. 2001 Jun;8(3):147-51.  
25  
26  
27 27. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. *Br J Dermatol*  
28  
29  
30 2004;150:186-94.  
31  
32  
33 28. Scow DT, Nolte RS, Shaughnessy AF. Medical treatments for balding in men. *Am Fam*  
34  
35  
36 *Physician* 1999;59:2189-94.  
37  
38  
39 29. Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: a  
40  
41  
42 community-based survey. *Br J Dermatol* 2010;163:371-7.  
43  
44  
45 30. Ahouansou S, Le Toumelin P, Crickx B, *et al.* Association of androgenetic alopecia and  
46  
47  
48 hypertension. *Eur J Dermatol* 2007;17:220-2.  
49  
50  
51 31. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, *et al.* Male androgenetic  
52  
53  
54 alopecia and cardiovascular risk factors: A case-control study. *Actas Dermosifilogr*  
55  
56  
57 2010;101:248-56.  
58  
59  
60

- 1  
2  
3  
4  
5  
6 32. Yudkin JS, Stehouwer CD, Emeis JJ, *et al.* C-reactive protein in healthy subjects: associations  
7  
8  
9 with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines  
10  
11  
12 originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999;19:972-8.  
13  
14  
15 33. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and  
16  
17  
18 prevention. *Circulation* 2003;107:363-9.  
19  
20  
21 34. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher  
22  
23  
24 levels of androgen receptors than those from non-balding scalp. *J Endocrinol* 1998;156:59-65.  
25  
26  
27 35. Demark-Wahnefried W, Lesko SM, Conaway MR, *et al.* Serum androgens: associations with  
28  
29  
30 prostate cancer risk and hair patterning. *J Androl* 1997;18:495-500.  
31  
32  
33 36. Fujimoto R, Morimoto I, Morita E, *et al.* Androgen receptors, 5 $\alpha$ -reductase activity and  
34  
35  
36 androgen-dependent proliferation of vascular smooth muscle cells. *J Steroid Biochem Mol Biol*  
37  
38  
39 1994;50:169-74.  
40  
41  
42 37. Reborn A. Baldness and coronary artery disease: the dermatologic point of view of a  
43  
44  
45 controversial issue. *Arch Dermatol* 2001;137:943-7.  
46  
47  
48 38. Llau ME, Viraben R, Montastruc JL. [Drug-induced alopecia: review of the literature]. *Therapie*  
49  
50  
51 1995;50:145-50.  
52  
53  
54 39. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its  
55  
56  
57 potential relationship to hair loss. *J Am Acad Dermatol* 2006;54:824-44.  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

40. Olsen EA. Iron deficiency and hair loss: the jury is still out. J Am Acad Dermatol 2006;54:903-6.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2012-002537 on 3 April 2013. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

## Figure legends

### Figure 1. Flow diagram of study selection.

### Figure 2. Association of baldness with CHD in the 3 cohort studies.

The forest plot shows the association between male pattern baldness and the risk of coronary heart disease (CHD). CI=confidence interval; RR=relative risk.

### Figure 3. Association of baldness with CHD in the 3 case-control studies.

The forest plot shows the association between male pattern baldness and the risk of coronary heart disease (CHD). CI=confidence interval; RR=relative risk.

### Figure 4. Association of baldness with CHD in studies using the modified Hamilton scale.

The forest plot shows the association between male pattern baldness and the risk of coronary heart disease (CHD). CI=confidence interval; RR=relative risk

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

---

First author,	Type of	Country	Subjects	CHD (events)	Assessment of baldness	Follow-up	Covariates used for adjustment
---------------	---------	---------	----------	--------------	------------------------	-----------	--------------------------------

---

For peer review only

Table 1. Summary of studies evaluating the association between baldness and coronary heart disease

year of publication	study					(years)	
Schnohr, 1995 (8)	Cohort	Denmark	5837	Myocardial infarction (750)	Simplified Hamilton (None, Frontoparietal, Crown-top, Combined)	12.0	Age, smoking, systolic blood pressure, cholesterol, triglycerides, physical activity, BMI, family history of MI, marital status, education, economic status, diabetes, and alcohol consumption
Ford, 1996 (9)	Cohort	USA	3994	Ischemic heart disease (965)	Personal scale (None, Minimum, Moderate, Severe)	14.0	Age, age squared, race, education, systolic blood pressure, antihypertensive medication, cholesterol, smoking, BMI, and diabetes mellitus
Lotufo, 2000 (10)	Cohort	USA	19112	Nonfatal MI, angina, coronary revascularization (1446)	Modified Hamilton (None, Frontal, Mild vertex, Moderate vertex, Severe vertex)	11.0	Age, aspirin assignment, beta carotene assignment, BMI, height (cm), hypertension, hypercholesterolemia, diabetes, parental history of MI, physical activity, smoking, and alcohol use.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

Lesko,	Case-	USA	1437	Non-fatal	Modified Hamilton (None,	-	Age, race, religion, years of education, BMI, use of
1993 (11)	control			Myocardial	Frontal only, Mild vertex,		alcohol and cigarettes, family history of myocardial
				infarction (665)	Moderate vertex, Severe vertex)		infarction, personal history of angina, hypertension,
							diabetes, hypercholesterolemia, gout, exercise,
							personality, and number of doctor visits in the past year.
Miric,	Case-	Croatia	1554	Non-fatal	Personal score ( None, Any,	-	Age, family history of MI, hypertension,
1998 (12)	control			Myocardial	Frontal, Parietal, Fronto-parietal)		hypercholesterolemia, BMI, diabetes, and smoking.
				infarction (842)			
Shahar,	Case-	USA	5056	Non-fatal	Modified Hamilton ( None,	-	Age, smoking, BMI, race-center, cholesterol-lowering
2008 (13)	control			Myocardial	Frontal, Mild vertex, Moderate		medication, antihypertensive medication, HDL,
				infarction (767)	vertex, Severe vertex)		diabetes, educational level, and family history of MI.


CHD, coronary heart disease; BMI, body mass index; MI, myocardial infarction; AGA, androgenic alopecia; HDL, high density lipoprotein;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig. 1



120x90mm (300 x 300 DPI)

ew only



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	7-9

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Page 1 of 2





# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7-9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7-9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9, Fig 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9, Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-10, Table 1, Fig 2-4
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-12, Fig 2-4
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10-13 Suppl.2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11-14
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18-19
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19-21



# PRISMA 2009 Checklist

doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49


## Supplementary Data 2. Newcastle-Ottawa quality assessment scale for observational studies

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Study reference (author, year)	Selection	Comparability	Outcome/Exposure
Cohort studies			
Schnohor, 1995 (8)	***	**	***
Ford, 1996 (9)	***	**	***
Lotufo, 2000 (10)	***	**	***
Case-control studies			
Lesko, 1993 (11)	**	**	**
Miric, 1998 (12)	***	**	**
Shahar, 2008 (13)	****	**	**

6/bmjopen-2013-002537 on 3 April 2013. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.


Fig. 2



90x116mm (300 x 300 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig. 3



90x116mm (300 x 300 DPI)

Fig. 4



90x116mm (300 x 300 DPI)